__key__
stringlengths
66
68
__url__
stringclasses
10 values
txt
stringlengths
0
8.83k
cells.json
listlengths
0
582
segments.json
listlengths
1
184
metadata.json
dict
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-0
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
2010 FORM 10-K
[ { "bbox": [ 0.35810100498484143, 0.375571649193307, 0.49648010355125416, 0.3842038365311702 ], "ocr": false, "ocr_confidence": 1, "text": "2010 FORM 10–K " } ]
[ { "bbox": [ 0.2312205553450197, 0.2520334139028576, 0.5445962023379197, 0.34065942289272033 ], "data": [], "index_in_doc": 0, "label": "picture", "text": "" }, { "bbox": [ 0.35698081249028296, 0.3743693033854167, 0.4969787091560427, 0.38447533774345466 ], "data": [], "index_in_doc": 1, "label": "text", "text": "2010 FORM 10-K" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 0 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-1
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2010 Commission File Number 001-12215 Quest Diagnostics Incorporated 3 Giralda Farms Madison, New Jersey 07940 (973) 520-2700 Delaware (State of Incorporation) 16-1387862 (I.R.S. Employer Identification Number) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $.01 par value per share New York Stock Exchange Title of Each Class Name of Each Exchange on Which Registered Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes X No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No X Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X] Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. Large accelerated filer company) X Accelerated filer Non-accelerated filer (do not check if a smaller reporting Smaller reporting company Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No X As of June 30, 2010, the aggregate market value of the approximately 146 million shares of voting and non-voting common equity held by non-affiliates of the registrant was approximately $7.3 billion, based on the closing price on such date of the registrant's Common Stock on the New York Stock Exchange. As of January 31, 2011, there were outstanding 171,164,282 shares of Common Stock, $.01 par value per share. Documents Incorporated by Reference Document Portions of the registrant's Proxy Statement to be filed by April 28, 2011. ........ Part of Form 10-K into which incorporated Part III Such Proxy Statement, except for the portions thereof which have been specifically incorporated by reference, shall not be deemed "filed" as part of this report on Form 10-K.
[ { "bbox": [ 0.06411426221553367, 0.03162439572856801, 0.5652430393604893, 0.04064543859255268 ], "ocr": false, "ocr_confidence": 1, "text": "UNITED STATES SECURITIES AND EXCHANGE COMMISSION" }, { "bbox": [ 0.06416382797519564, 0.04436710206637133, 0.2627500214584629, 0.05543660325870051 ], "ocr": false, "ocr_confidence": 1, "text": "WASHINGTON, DC 20549" }, { "bbox": [ 0.06411426221553367, 0.0672594170308509, 0.15555209386012644, 0.07626775398108238 ], "ocr": false, "ocr_confidence": 1, "text": "FORM 10-K" }, { "bbox": [ 0.06409774451311152, 0.12985607551584452, 0.4101303885034463, 0.14134549546515804 ], "ocr": false, "ocr_confidence": 1, "text": "Annual Report Pursuant to Section 13 or 15(d) of" }, { "bbox": [ 0.06406469645587168, 0.1425898955090597, 0.317369173217571, 0.15402841385296934 ], "ocr": false, "ocr_confidence": 1, "text": "the Securities Exchange Act of 1934" }, { "bbox": [ 0.06404817875344955, 0.15533260184686304, 0.38757491230371577, 0.16579143967512772 ], "ocr": false, "ocr_confidence": 1, "text": "For the Fiscal Year Ended December 31, 2010" }, { "bbox": [ 0.06431252525418156, 0.16801170066550927, 0.31737081802899564, 0.17691823440493296 ], "ocr": false, "ocr_confidence": 1, "text": "Commission File Number 001-12215" }, { "bbox": [ 0.06465947924561762, 0.19052416337404215, 0.38319212247680867, 0.20646688916826308 ], "ocr": false, "ocr_confidence": 1, "text": "Quest Diagnostics Incorporated" }, { "bbox": [ 0.06456034772629367, 0.2094201176863825, 0.17530382450540266, 0.2182630439066491 ], "ocr": false, "ocr_confidence": 1, "text": "3 Giralda Farms" }, { "bbox": [ 0.06404817875344955, 0.22469738099157888, 0.2583816300577192, 0.2361358993354885 ], "ocr": false, "ocr_confidence": 1, "text": "Madison, New Jersey 07940" }, { "bbox": [ 0.06464296154319549, 0.23991103677761813, 0.1689941760517076, 0.25089151862328385 ], "ocr": false, "ocr_confidence": 1, "text": "(973) 520-2700" }, { "bbox": [ 0.06408122048449161, 0.2578754839160281, 0.13054812606887436, 0.2666293907896312 ], "ocr": false, "ocr_confidence": 1, "text": "Delaware" }, { "bbox": [ 0.06454383002387153, 0.2705215317688378, 0.2258388082779462, 0.281756521641523 ], "ocr": false, "ocr_confidence": 1, "text": "(State of Incorporation)" }, { "bbox": [ 0.06492382574634963, 0.28820613700311304, 0.14333592758052188, 0.2971126707425367 ], "ocr": false, "ocr_confidence": 1, "text": "16-1387862" }, { "bbox": [ 0.06454383002387153, 0.30101245086007344, 0.33667974013396557, 0.3123110482519157 ], "ocr": false, "ocr_confidence": 1, "text": "(I.R.S. Employer Identification Number)" }, { "bbox": [ 0.06442817447592765, 0.3291824750059866, 0.4857387764141532, 0.340608287436143 ], "ocr": false, "ocr_confidence": 1, "text": "Securities registered pursuant to Section 12(b) of the Act:" }, { "bbox": [ 0.06482470055322347, 0.349667564966974, 0.8725021134561567, 0.36096612338362066 ], "ocr": false, "ocr_confidence": 1, "text": "Title of Each Class Name of Each Exchange on Which Registered" }, { "bbox": [ 0.06431252525418156, 0.36438498856311863, 0.7398278788349917, 0.37638334661608 ], "ocr": false, "ocr_confidence": 1, "text": "Common Stock, $.01 par value per share New York Stock Exchange" }, { "bbox": [ 0.06442817447592765, 0.38833594778945163, 0.48489288785564366, 0.3997617602196081 ], "ocr": false, "ocr_confidence": 1, "text": "Securities registered pursuant to Section 12(g) of the Act: " }, { "bbox": [ 0.5530333764122097, 0.3887430826822917, 0.5882246482431592, 0.39728063824533044 ], "ocr": false, "ocr_confidence": 1, "text": "None" }, { "bbox": [ 0.06414730394657571, 0.4097714089190214, 0.8869569186942889, 0.4212735737572837 ], "ocr": false, "ocr_confidence": 1, "text": "Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act." }, { "bbox": [ 0.06421339373485761, 0.42530696084520675, 0.08884728528176176, 0.4338318104944923 ], "ocr": false, "ocr_confidence": 1, "text": "Yes " }, { "bbox": [ 0.11610120327318486, 0.4253086757538115, 0.18050454109660033, 0.43384623131685024 ], "ocr": false, "ocr_confidence": 1, "text": "X No" }, { "bbox": [ 0.06414730394657571, 0.4495229903765565, 0.8722774069107587, 0.4610251552148188 ], "ocr": false, "ocr_confidence": 1, "text": "Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the" }, { "bbox": [ 0.06404817875344955, 0.4648639001761055, 0.1950852882802783, 0.47630241852001515 ], "ocr": false, "ocr_confidence": 1, "text": "Exchange Act. Yes " }, { "bbox": [ 0.2553750666022103, 0.4651312310424649, 0.2748046166465848, 0.47366878660550366 ], "ocr": false, "ocr_confidence": 1, "text": "No " }, { "bbox": [ 0.30188094561372825, 0.4651312310424649, 0.31334702727411123, 0.4735542774809427 ], "ocr": false, "ocr_confidence": 1, "text": "X" }, { "bbox": [ 0.06414818328806812, 0.48927305180146474, 0.9036828795475746, 0.500775216639727 ], "ocr": false, "ocr_confidence": 1, "text": "Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the" }, { "bbox": [ 0.06454470936536394, 0.5046139616010137, 0.927255810789801, 0.5160524799449234 ], "ocr": false, "ocr_confidence": 1, "text": "Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required" }, { "bbox": [ 0.06406557579736409, 0.5198186920672693, 0.7193136895276223, 0.5312572104111789 ], "ocr": false, "ocr_confidence": 1, "text": "to file such reports), and (2) has been subject to such filing requirements for the past 90 days." }, { "bbox": [ 0.06421427307635003, 0.5353630913628472, 0.08884816462325418, 0.5438879410121328 ], "ocr": false, "ocr_confidence": 1, "text": "Yes " }, { "bbox": [ 0.11610120327318486, 0.5353637929163674, 0.18050454109660033, 0.5439013484794061 ], "ocr": false, "ocr_confidence": 1, "text": "X No" }, { "bbox": [ 0.06414730394657571, 0.5562387517585609, 0.9277638297768968, 0.5676772701024705 ], "ocr": false, "ocr_confidence": 1, "text": "Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every" }, { "bbox": [ 0.06414730394657571, 0.5714523685694045, 0.9263993954381737, 0.5829545334076668 ], "ocr": false, "ocr_confidence": 1, "text": "Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)" }, { "bbox": [ 0.06429600122556164, 0.5867932783689536, 0.9091388961766688, 0.5982317967128632 ], "ocr": false, "ocr_confidence": 1, "text": "during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files)." }, { "bbox": [ 0.06421339373485761, 0.602337716639727, 0.08884728528176176, 0.6108625662890126 ], "ocr": false, "ocr_confidence": 1, "text": "Yes " }, { "bbox": [ 0.11610120327318486, 0.6023381063916826, 0.18050454109660033, 0.6108756619547214 ], "ocr": false, "ocr_confidence": 1, "text": "X No" }, { "bbox": [ 0.06414730394657571, 0.6231495356651101, 0.9207571355462272, 0.6346517005033725 ], "ocr": false, "ocr_confidence": 1, "text": "Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter)" }, { "bbox": [ 0.06411426221553367, 0.6384904454646592, 0.9152488898282027, 0.6499289638085688 ], "ocr": false, "ocr_confidence": 1, "text": "is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information" }, { "bbox": [ 0.06469252097665967, 0.6537677087698556, 0.8256728139089707, 0.6652062271137652 ], "ocr": false, "ocr_confidence": 1, "text": "statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]" }, { "bbox": [ 0.06414730394657571, 0.6749092579496927, 0.9111908110813122, 0.6863477957812001 ], "ocr": false, "ocr_confidence": 1, "text": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a" }, { "bbox": [ 0.06469252097665967, 0.690186521254889, 0.869718080334007, 0.7016250590863965 ], "ocr": false, "ocr_confidence": 1, "text": "smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting" }, { "bbox": [ 0.06426295949451959, 0.7054637650724876, 0.3860384306899746, 0.716902302903995 ], "ocr": false, "ocr_confidence": 1, "text": "company” in Rule 12b-2 of the Exchange Act." }, { "bbox": [ 0.06404817875344955, 0.7266053532275204, 0.21800917693433872, 0.7380438910590278 ], "ocr": false, "ocr_confidence": 1, "text": "Large accelerated filer " }, { "bbox": [ 0.24452991390702736, 0.7266070876237228, 0.4027551805992822, 0.7353991122385856 ], "ocr": false, "ocr_confidence": 1, "text": "X Accelerated filer " }, { "bbox": [ 0.47246276956687916, 0.7266070876237228, 0.6151411015398269, 0.7354118376399366 ], "ocr": false, "ocr_confidence": 1, "text": "Non-accelerated filer " }, { "bbox": [ 0.6787689866908945, 0.7266070876237228, 0.9251012596522595, 0.7380456254552303 ], "ocr": false, "ocr_confidence": 1, "text": "(do not check if a smaller reporting" }, { "bbox": [ 0.06426492694203138, 0.741973428738376, 0.12927791411999248, 0.7533228887604266 ], "ocr": false, "ocr_confidence": 1, "text": "company)" }, { "bbox": [ 0.06454579747138332, 0.7630259195963541, 0.24938590332841004, 0.7744644574278616 ], "ocr": false, "ocr_confidence": 1, "text": "Smaller reporting company" }, { "bbox": [ 0.06414730394657571, 0.7841688718832316, 0.8591774201907131, 0.795607409714739 ], "ocr": false, "ocr_confidence": 1, "text": "Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)." }, { "bbox": [ 0.06421339373485761, 0.7997133296416028, 0.08884728528176176, 0.8082381598032906 ], "ocr": false, "ocr_confidence": 1, "text": "Yes " }, { "bbox": [ 0.1490405511302537, 0.7997134660547873, 0.16847010117462816, 0.808251021617826 ], "ocr": false, "ocr_confidence": 1, "text": "No " }, { "bbox": [ 0.19554648075135392, 0.7997134660547873, 0.20701256241173688, 0.8081365124932651 ], "ocr": false, "ocr_confidence": 1, "text": "X" }, { "bbox": [ 0.06409799123482522, 0.8239061689315932, 0.9273973151819029, 0.8353574321644516 ], "ocr": false, "ocr_confidence": 1, "text": "As of June 30, 2010, the aggregate market value of the approximately 146 million shares of voting and non-voting common" }, { "bbox": [ 0.06426320621623328, 0.8386363179290889, 0.9257765939184287, 0.8506347052134469 ], "ocr": false, "ocr_confidence": 1, "text": "equity held by non-affiliates of the registrant was approximately $7.3 billion, based on the closing price on such date of the" }, { "bbox": [ 0.06393276992721937, 0.8544734209433369, 0.496967170171279, 0.8659119685186433 ], "ocr": false, "ocr_confidence": 1, "text": "registrant’s Common Stock on the New York Stock Exchange." }, { "bbox": [ 0.06409799123482522, 0.875055159645519, 0.8432440053961962, 0.887053546929877 ], "ocr": false, "ocr_confidence": 1, "text": "As of January 31, 2011, there were outstanding 171,164,282 shares of Common Stock, $.01 par value per share." }, { "bbox": [ 0.0640814672062053, 0.8966547940425946, 0.3433927722633577, 0.908029714611146 ], "ocr": false, "ocr_confidence": 1, "text": "Documents Incorporated by Reference" }, { "bbox": [ 0.06405808557918416, 0.9149396952389148, 0.12899312134801255, 0.9228181315260068 ], "ocr": false, "ocr_confidence": 1, "text": "Document" }, { "bbox": [ 0.7681629187234401, 0.905510455408011, 0.905858383052187, 0.9126663305445801 ], "ocr": false, "ocr_confidence": 1, "text": "Part of Form 10-K into" }, { "bbox": [ 0.7811359766110852, 0.9156467540054029, 0.8929791553301202, 0.9247468336940877 ], "ocr": false, "ocr_confidence": 1, "text": "which incorporated" }, { "bbox": [ 0.06411426221553367, 0.93310529336162, 0.5796103406308303, 0.9445438311931273 ], "ocr": false, "ocr_confidence": 1, "text": "Portions of the registrant’s Proxy Statement to be filed by April 28, 2011. " }, { "bbox": [ 0.5851119564935738, 0.9405231646346559, 0.6376246109135313, 0.9419100433778337 ], "ocr": false, "ocr_confidence": 1, "text": "........ " }, { "bbox": [ 0.8124954451375933, 0.9333724878147949, 0.8615335999041253, 0.9418973179764827 ], "ocr": false, "ocr_confidence": 1, "text": "Part III" }, { "bbox": [ 0.06454376676189366, 0.9506269968941446, 0.9138937676526223, 0.9620655395975515 ], "ocr": false, "ocr_confidence": 1, "text": "Such Proxy Statement, except for the portions thereof which have been specifically incorporated by reference, shall not be" }, { "bbox": [ 0.06429593796358378, 0.9659042553274415, 0.4246132820597533, 0.9773300726294974 ], "ocr": false, "ocr_confidence": 1, "text": "deemed “filed” as part of this report on Form 10-K." } ]
[ { "bbox": [ 0.0628814697265625, 0.03106471192029853, 0.5656190685569548, 0.05543660325870051 ], "data": [], "index_in_doc": 2, "label": "section_header", "text": "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549" }, { "bbox": [ 0.06314869464728765, 0.06592116471603608, 0.15603036706522724, 0.07677326226752075 ], "data": [], "index_in_doc": 3, "label": "text", "text": "FORM 10-K" }, { "bbox": [ 0.06252214169225487, 0.12882190767680396, 0.410539339233196, 0.17867710703025225 ], "data": [], "index_in_doc": 4, "label": "text", "text": "Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2010 Commission File Number 001-12215" }, { "bbox": [ 0.06272544038434132, 0.1889794984235313, 0.38319212247680867, 0.2067675438268279 ], "data": [], "index_in_doc": 5, "label": "section_header", "text": "Quest Diagnostics Incorporated" }, { "bbox": [ 0.06300139545801267, 0.2080923886743694, 0.17583020211847664, 0.21921754644596106 ], "data": [], "index_in_doc": 6, "label": "text", "text": "3 Giralda Farms" }, { "bbox": [ 0.06234295213993509, 0.22307079017999681, 0.25888107072061567, 0.25089151862328385 ], "data": [], "index_in_doc": 7, "label": "text", "text": "Madison, New Jersey 07940 (973) 520-2700" }, { "bbox": [ 0.0623294520338574, 0.2560969677921456, 0.13171568913246268, 0.26765584153995053 ], "data": [], "index_in_doc": 8, "label": "section_header", "text": "Delaware" }, { "bbox": [ 0.06247873764923754, 0.26939039364323913, 0.22718067074296486, 0.2824159040000399 ], "data": [], "index_in_doc": 9, "label": "text", "text": "(State of Incorporation)" }, { "bbox": [ 0.0631388574097287, 0.2867810479525862, 0.14379008531965823, 0.2980578192349138 ], "data": [], "index_in_doc": 10, "label": "text", "text": "16-1387862" }, { "bbox": [ 0.062296226843079526, 0.2998355558548851, 0.3377273078779281, 0.31309585278975094 ], "data": [], "index_in_doc": 11, "label": "text", "text": "(I.R.S. Employer Identification Number)" }, { "bbox": [ 0.0621416398739538, 0.3279793886693806, 0.48621511380273114, 0.34134039750957856 ], "data": [], "index_in_doc": 12, "label": "section_header", "text": "Securities registered pursuant to Section 12(b) of the Act:" }, { "bbox": [ 0.06431252525418156, 0.36438498856311863, 0.7398278788349917, 0.37638334661608 ], "data": [], "index_in_doc": 13, "label": "text", "text": "Common Stock, $.01 par value per share New York Stock Exchange" }, { "bbox": [ 0.06482470055322347, 0.34865218317219426, 0.8733898055296434, 0.3764243095466156 ], "data": [], "index_in_doc": 14, "label": "text", "text": "Title of Each Class Name of Each Exchange on Which Registered" }, { "bbox": [ 0.06230913228656522, 0.3874278257328584, 0.485517106443693, 0.40107588688837004 ], "data": [], "index_in_doc": 15, "label": "section_header", "text": "Securities registered pursuant to Section 12(g) of the Act:" }, { "bbox": [ 0.5509800444392621, 0.3877759132044221, 0.5885179813821517, 0.3982255139113386 ], "data": [], "index_in_doc": 16, "label": "text", "text": "None" }, { "bbox": [ 0.06248498160645341, 0.4088357703743614, 0.8873050114013267, 0.42152297603368455 ], "data": [], "index_in_doc": 17, "label": "text", "text": "Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act." }, { "bbox": [ 0.06263692422490412, 0.42474174255916747, 0.08967284776678133, 0.43499475237966956 ], "data": [], "index_in_doc": 18, "label": "text", "text": "Yes" }, { "bbox": [ 0.11610120327318486, 0.42452995134648386, 0.18154420109332892, 0.43452864801594426 ], "data": [], "index_in_doc": 19, "label": "text", "text": "X No" }, { "bbox": [ 0.06283757224011777, 0.44812284545118936, 0.8725602132566335, 0.47649312415189976 ], "data": [], "index_in_doc": 20, "label": "text", "text": "Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No X" }, { "bbox": [ 0.06237486148157325, 0.4880257286178959, 0.9280733579822243, 0.5320870312998882 ], "data": [], "index_in_doc": 21, "label": "text", "text": "Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days." }, { "bbox": [ 0.06421427307635003, 0.5353630913628472, 0.08884816462325418, 0.5438879410121328 ], "data": [], "index_in_doc": 22, "label": "text", "text": "Yes" }, { "bbox": [ 0.11610120327318486, 0.5331330475983797, 0.1813849453902363, 0.544015156050447 ], "data": [], "index_in_doc": 23, "label": "text", "text": "X No" }, { "bbox": [ 0.0625016701162158, 0.5552629297872765, 0.9277638297768968, 0.60006402065623 ], "data": [], "index_in_doc": 24, "label": "text", "text": "Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files)." }, { "bbox": [ 0.06421339373485761, 0.602337716639727, 0.08884728528176176, 0.6108625662890126 ], "data": [], "index_in_doc": 25, "label": "text", "text": "Yes" }, { "bbox": [ 0.11610120327318486, 0.6012617284158485, 0.18162542947291538, 0.6119292784163474 ], "data": [], "index_in_doc": 26, "label": "text", "text": "X No" }, { "bbox": [ 0.06268152391930322, 0.6217384387097901, 0.9215489730708437, 0.6653759640904374 ], "data": [], "index_in_doc": 27, "label": "text", "text": "Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]" }, { "bbox": [ 0.06259092644079407, 0.673383262117856, 0.911892158672782, 0.7171009594757742 ], "data": [], "index_in_doc": 28, "label": "text", "text": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of \"large accelerated filer,\" \"accelerated filer\" and \"smaller reporting company\" in Rule 12b-2 of the Exchange Act." }, { "bbox": [ 0.06404817875344955, 0.7266053532275204, 0.21800917693433872, 0.7533228887604266 ], "data": [], "index_in_doc": 29, "label": "text", "text": "Large accelerated filer company)" }, { "bbox": [ 0.24452991390702736, 0.7255501582704741, 0.4031769608581442, 0.7367974643049569 ], "data": [], "index_in_doc": 30, "label": "text", "text": "X Accelerated filer" }, { "bbox": [ 0.47071380362186466, 0.7256836093400783, 0.6156593942721289, 0.7366624542275303 ], "data": [], "index_in_doc": 31, "label": "text", "text": "Non-accelerated filer" }, { "bbox": [ 0.6768226433749223, 0.7257493994701868, 0.9260463429920709, 0.738341661553121 ], "data": [], "index_in_doc": 32, "label": "text", "text": "(do not check if a smaller reporting" }, { "bbox": [ 0.06248422246271896, 0.7619582136015326, 0.25018991245756894, 0.7754934415658924 ], "data": [], "index_in_doc": 33, "label": "text", "text": "Smaller reporting company" }, { "bbox": [ 0.06243401775708048, 0.7832544943077506, 0.8600887975487148, 0.7965043458902059 ], "data": [], "index_in_doc": 34, "label": "text", "text": "Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)." }, { "bbox": [ 0.06256305321334409, 0.7993246689914592, 0.09090655122823384, 0.8098332391692609 ], "data": [], "index_in_doc": 35, "label": "text", "text": "Yes" }, { "bbox": [ 0.1490405511302537, 0.7997134660547873, 0.16847010117462816, 0.808251021617826 ], "data": [], "index_in_doc": 36, "label": "text", "text": "No" }, { "bbox": [ 0.19554648075135392, 0.7997134660547873, 0.20701256241173688, 0.8081365124932651 ], "data": [], "index_in_doc": 37, "label": "text", "text": "X" }, { "bbox": [ 0.06207198211011997, 0.8225273044630029, 0.9275403378614738, 0.866224189066491 ], "data": [], "index_in_doc": 38, "label": "text", "text": "As of June 30, 2010, the aggregate market value of the approximately 146 million shares of voting and non-voting common equity held by non-affiliates of the registrant was approximately $7.3 billion, based on the closing price on such date of the registrant's Common Stock on the New York Stock Exchange." }, { "bbox": [ 0.06221339160925515, 0.8740953077606162, 0.8445371308334629, 0.8876158810514447 ], "data": [], "index_in_doc": 39, "label": "text", "text": "As of January 31, 2011, there were outstanding 171,164,282 shares of Common Stock, $.01 par value per share." }, { "bbox": [ 0.06317117795422303, 0.8955754734394955, 0.34424144434889353, 0.9087419181034483 ], "data": [], "index_in_doc": 40, "label": "section_header", "text": "Documents Incorporated by Reference" }, { "bbox": [ 0.06275370583605411, 0.9140836245559946, 0.12905757265106757, 0.9247723380876836 ], "data": [], "index_in_doc": 41, "label": "section_header", "text": "Document" }, { "bbox": [ 0.06263640547668559, 0.9321040400752315, 0.5796103406308303, 0.9455437008600734 ], "data": [], "index_in_doc": 42, "label": "text", "text": "Portions of the registrant's Proxy Statement to be filed by April 28, 2011." }, { "bbox": [ 0.5851119564935738, 0.9405231646346559, 0.6376246109135313, 0.9419100433778337 ], "data": [], "index_in_doc": 43, "label": "text", "text": "........" }, { "bbox": [ 0.7667678655874275, 0.9041698938128592, 0.907234761252332, 0.9251281816231641 ], "data": [], "index_in_doc": 44, "label": "text", "text": "Part of Form 10-K into which incorporated" }, { "bbox": [ 0.8119833267743315, 0.9318915473090278, 0.8616924127733727, 0.9429742221174569 ], "data": [], "index_in_doc": 45, "label": "text", "text": "Part III" }, { "bbox": [ 0.06288996581019059, 0.9492521127674011, 0.9148115218179934, 0.9778620889208174 ], "data": [], "index_in_doc": 46, "label": "text", "text": "Such Proxy Statement, except for the portions thereof which have been specifically incorporated by reference, shall not be deemed \"filed\" as part of this report on Form 10-K." }, { "bbox": [ 0.7822345082044206, 0.08104658065932312, 0.9372319716521559, 0.1250917476103528 ], "data": [], "index_in_doc": 47, "label": "picture", "text": "" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 1 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-2
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
TABLE OF CONTENTS TABLE OF CONTENTS i
[ { "bbox": [ 0.40922047882333124, 0.042774731476492654, 0.5905398341949109, 0.05179577434047733 ], "ocr": false, "ocr_confidence": 1, "text": "TABLE OF CONTENTS" }, { "bbox": [ 0.49697364819781303, 0.06243756173670977, 0.8800957776223052, 0.0713951529823196 ], "ocr": false, "ocr_confidence": 1, "text": "Item Page" }, { "bbox": [ 0.10382293270990425, 0.0797432501197318, 0.8806415513577943, 0.08854798064834771 ], "ocr": false, "ocr_confidence": 1, "text": "Item 1. Business............................................................................. 1" }, { "bbox": [ 0.2031829479717299, 0.09502051342492816, 0.8806330489479685, 0.10645903176883781 ], "ocr": false, "ocr_confidence": 1, "text": "Our Strategy and Strengths ........................................................... 1" }, { "bbox": [ 0.20290207744237795, 0.11029777673012452, 0.8812476517153814, 0.12172358916028098 ], "ocr": false, "ocr_confidence": 1, "text": "Business Operations.................................................................. 3" }, { "bbox": [ 0.20290207744237795, 0.12557504003532088, 0.8816987855319756, 0.13701355837923052 ], "ocr": false, "ocr_confidence": 1, "text": "The United States Clinical Testing Market . ........................................... 9" }, { "bbox": [ 0.20314992521928119, 0.1407797315263809, 0.8806283928663972, 0.1496226577466475 ], "ocr": false, "ocr_confidence": 1, "text": "General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11" }, { "bbox": [ 0.2029021027471691, 0.15605699483157726, 0.8819086128601783, 0.16749551317548692 ], "ocr": false, "ocr_confidence": 1, "text": "Billing and Reimbursement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14" }, { "bbox": [ 0.20290211539956468, 0.17127065061761654, 0.8813551464681799, 0.18277277648068327 ], "ocr": false, "ocr_confidence": 1, "text": "Regulation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15" }, { "bbox": [ 0.20286906734232482, 0.18661152144197, 0.8814641595084474, 0.1954544476622366 ], "ocr": false, "ocr_confidence": 1, "text": "Available Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18" }, { "bbox": [ 0.20281950790886064, 0.20188878474716634, 0.8816905867796434, 0.21332730309107598 ], "ocr": false, "ocr_confidence": 1, "text": "Executive Officers of the Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19" }, { "bbox": [ 0.10382463445710899, 0.2171660480523627, 0.8819812882203566, 0.2260089742726293 ], "ocr": false, "ocr_confidence": 1, "text": "Item 1A. Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20" }, { "bbox": [ 0.20308548656862174, 0.23244331135755908, 0.8814526205236837, 0.2438818297014687 ], "ocr": false, "ocr_confidence": 1, "text": "Cautionary Factors That May Affect Future Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28" }, { "bbox": [ 0.10382627294233585, 0.24772057466275543, 0.8819764297004561, 0.25656350088302204 ], "ocr": false, "ocr_confidence": 1, "text": "Item 1B. Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30" }, { "bbox": [ 0.10382627294233585, 0.26292526615381545, 0.8819847296719527, 0.2743510785839719 ], "ocr": false, "ocr_confidence": 1, "text": "Item 2. Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30" }, { "bbox": [ 0.10382627294233585, 0.2782025294590118, 0.8806264697022699, 0.28964104780292144 ], "ocr": false, "ocr_confidence": 1, "text": "Item 3. Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31" }, { "bbox": [ 0.10382627294233585, 0.29347979276420816, 0.8812344932239843, 0.30232271898447477 ], "ocr": false, "ocr_confidence": 1, "text": "Item 4. Removed and Reserved . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33" }, { "bbox": [ 0.10382627294233585, 0.30869344855024744, 0.7557319906813589, 0.3201955744133142 ], "ocr": false, "ocr_confidence": 1, "text": "Item 5. Market for Registrant’s Common Stock, Related Stockholder Matters and Issuer" }, { "bbox": [ 0.21943540557304622, 0.32149976240720785, 0.8819086128601783, 0.3329382807511175 ], "ocr": false, "ocr_confidence": 1, "text": "Purchases of Equity Securities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34" }, { "bbox": [ 0.10382794305855164, 0.3367134181932471, 0.881351907454913, 0.3456199519326708 ], "ocr": false, "ocr_confidence": 1, "text": "Item 6. Selected Financial Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35" }, { "bbox": [ 0.10382794305855164, 0.35198179515385536, 0.742106676497072, 0.363420313497765 ], "ocr": false, "ocr_confidence": 1, "text": "Item 7. Management’s Discussion and Analysis of Financial Condition and Results of" }, { "bbox": [ 0.2197344575948383, 0.36466085499730605, 0.8813567659748134, 0.37615031392181514 ], "ocr": false, "ocr_confidence": 1, "text": "Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35" }, { "bbox": [ 0.103827962037145, 0.3799381183025024, 0.8813353075119196, 0.39093134503711685 ], "ocr": false, "ocr_confidence": 1, "text": "Item 7A. Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . 35" }, { "bbox": [ 0.10382797468954058, 0.39526628321310264, 0.8818376582257981, 0.40671754644596103 ], "ocr": false, "ocr_confidence": 1, "text": "Item 8. Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36" }, { "bbox": [ 0.10382797468954058, 0.41055629140724775, 0.7439091873801565, 0.4219948097511574 ], "ocr": false, "ocr_confidence": 1, "text": "Item 9. Changes in and Disagreements with Accountants on Accounting and Financial" }, { "bbox": [ 0.21943710099405317, 0.42328625285610233, 0.8818523350046642, 0.4321418849901221 ], "ocr": false, "ocr_confidence": 1, "text": "Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36" }, { "bbox": [ 0.10382798734193616, 0.4384909833223579, 0.8818474764847637, 0.4474484186671855 ], "ocr": false, "ocr_confidence": 1, "text": "Item 9A. Controls and Procedures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36" }, { "bbox": [ 0.10382797468954058, 0.4537682466275543, 0.8818508167171952, 0.46272568197238184 ], "ocr": false, "ocr_confidence": 1, "text": "Item 9B. Other Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36" }, { "bbox": [ 0.10382797468954058, 0.4690582548216994, 0.8815187166381634, 0.48048406725185583 ], "ocr": false, "ocr_confidence": 1, "text": "Item 10. Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37" }, { "bbox": [ 0.10382797468954058, 0.48433551812689574, 0.8815335958553586, 0.4957613305570522 ], "ocr": false, "ocr_confidence": 1, "text": "Item 11. Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37" }, { "bbox": [ 0.10382797468954058, 0.4996127814320921, 0.7553241280576285, 0.5110512997760017 ], "ocr": false, "ocr_confidence": 1, "text": "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related" }, { "bbox": [ 0.21986664982379767, 0.5123554877698955, 0.8815335958553586, 0.5211983750149665 ], "ocr": false, "ocr_confidence": 1, "text": "Stockholders’ Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37" }, { "bbox": [ 0.10382797468954058, 0.5276327510750918, 0.8814444217713516, 0.5390585635052483 ], "ocr": false, "ocr_confidence": 1, "text": "Item 13. Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . . . 38" }, { "bbox": [ 0.10382797468954058, 0.5428374815413474, 0.8814609204951803, 0.554275999885257 ], "ocr": false, "ocr_confidence": 1, "text": "Item 14. Principal Accounting Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38" }, { "bbox": [ 0.10382797468954058, 0.5580510593769955, 0.881692206286277, 0.5685735047244173 ], "ocr": false, "ocr_confidence": 1, "text": "Item 15. Exhibits, Financial Statement Schedules. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39" }, { "bbox": [ 0.1042245007668364, 0.5733919691765446, 0.8806198904565713, 0.5848304875204542 ], "ocr": false, "ocr_confidence": 1, "text": "Selected Historical Financial Data of Our Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41" }, { "bbox": [ 0.10372884949641441, 0.5886691935065453, 0.881213135980255, 0.600107711850455 ], "ocr": false, "ocr_confidence": 1, "text": "Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . . . 43" }, { "bbox": [ 0.10381145698711844, 0.603933711922793, 0.8812229542392206, 0.6153849751556514 ], "ocr": false, "ocr_confidence": 1, "text": "Report of Management on Internal Control Over Financial Reporting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63" }, { "bbox": [ 0.10381145698711844, 0.6192236811417425, 0.8806777878187189, 0.6306621994856522 ], "ocr": false, "ocr_confidence": 1, "text": "Report of Independent Registered Public Accounting Firm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1" }, { "bbox": [ 0.10399319599714643, 0.6345009444469388, 0.8820177271196102, 0.6433438316920099 ], "ocr": false, "ocr_confidence": 1, "text": "Consolidated Financial Statements and Related Notes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2" }, { "bbox": [ 0.1042245007668364, 0.6497781687769396, 0.525928351811904, 0.6612166871208492 ], "ocr": false, "ocr_confidence": 1, "text": "Supplementary Data: Quarterly Operating Results (unaudited) " }, { "bbox": [ 0.5315274923397336, 0.657196044921875, 0.8160910535214553, 0.6585828993055556 ], "ocr": false, "ocr_confidence": 1, "text": "........................................ " }, { "bbox": [ 0.8514508552614531, 0.6498672270987987, 0.8806446891518968, 0.6584683901809946 ], "ocr": false, "ocr_confidence": 1, "text": "F-41" }, { "bbox": [ 0.10422443750485852, 0.6649828992431952, 0.43905538429272906, 0.6738258059758641 ], "ocr": false, "ocr_confidence": 1, "text": "Schedule II – Valuation Accounts and Reserves . " }, { "bbox": [ 0.4445603403879042, 0.6724007753881306, 0.8160959120413557, 0.6737876297718112 ], "ocr": false, "ocr_confidence": 1, "text": ".................................................... " }, { "bbox": [ 0.8514508552614531, 0.6650719575650543, 0.8812560529060427, 0.6738258059758641 ], "ocr": false, "ocr_confidence": 1, "text": "F-43" }, { "bbox": [ 0.49791564435310426, 0.9506181787561487, 0.5018313077354115, 0.959308414775902 ], "ocr": false, "ocr_confidence": 1, "text": "i" } ]
[ { "bbox": [ 0.40761342214707713, 0.04239230685763889, 0.5916042549297782, 0.05251003377434547 ], "data": [], "index_in_doc": 48, "label": "caption", "text": "TABLE OF CONTENTS" }, { "bbox": [ 0.10225480745483197, 0.06102065747725096, 0.8846206791563018, 0.676054310220107 ], "data": [ { "html_seq": "<table><tr><td>Item Page</td></tr><tr><td>Item 1. Business............................................................................. 1</td></tr><tr><td>Our Strategy and Strengths ........................................................... 1</td></tr><tr><td>Business Operations.................................................................. 3</td></tr><tr><td>The United States Clinical Testing Market . ........................................... 9</td></tr><tr><td>General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11</td></tr><tr><td>Billing and Reimbursement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14</td></tr><tr><td>Regulation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15</td></tr><tr><td>Available Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18</td></tr><tr><td>Executive Officers of the Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19</td></tr><tr><td>Item 1A. Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20</td></tr><tr><td>Cautionary Factors That May Affect Future Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28</td></tr><tr><td>Item 1B. Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30</td></tr><tr><td>Item 2. Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30</td></tr><tr><td>Item 3. Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31</td></tr><tr><td>Item 4. Removed and Reserved . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33</td></tr><tr><td>Item 5. Market for Registrant's Common Stock, Related Stockholder Matters and Issuer Purchases of Equity Securities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34</td></tr><tr><td>Item 6. Selected Financial Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35</td></tr><tr><td>Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35</td></tr><tr><td>Item 7A. Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . 35</td></tr><tr><td>Item 8. Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36</td></tr><tr><td>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36</td></tr><tr><td>Item 9A. Controls and Procedures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36</td></tr><tr><td>Item 9B. Other Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36</td></tr><tr><td>Item 10. Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37</td></tr><tr><td>Item 11. Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37</td></tr><tr><td>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders' Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37</td></tr><tr><td>Item 13. Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . . . 38</td></tr><tr><td>Item 14. Principal Accounting Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38</td></tr><tr><td>Item 15. Exhibits, Financial Statement Schedules. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39</td></tr></table>", "otsl_seq": "" } ], "index_in_doc": 49, "label": "table", "text": "TABLE OF CONTENTS" }, { "bbox": [ 0.49647726941464554, 0.9498917736769636, 0.5027329680536121, 0.9594114651929677 ], "data": [], "index_in_doc": 50, "label": "page_footer", "text": "i" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 2 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-3
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
Item 1. Business Quest Diagnostics Incorporated is the world's leading provider of diagnostic testing, information and services. We provide insights that enable patients, physicians and others to make better healthcare decisions. Quest Diagnostics was incorporated in Delaware in 1990; its predecessor companies date back to 1967. We conduct business through our headquarters in Madison, New Jersey, and our laboratories, patient service centers, offices and other facilities around the United States and in selected locations outside the United States. Unless the context otherwise requires, the terms "Quest Diagnostics," the "Company," "we" and "our" mean Quest Diagnostics Incorporated and its consolidated subsidiaries. During 2010, we generated net revenues of $7.4 billion and processed approximately 146 million test requisitions. Additional financial information concerning Quest Diagnostics, including our consolidated subsidiaries and business segments, for each of the years ended December 31, 2010, December 31, 2009 and December 31, 2008 is included in the consolidated financial statements and notes thereto in "Financial Statements and Supplementary Data" in Part II, Item 8. OUR STRATEGY AND STRENGTHS Our mission is to be the undisputed world leader in diagnostic testing, information and services. We are dedicated to improving the health of patients through unsurpassed diagnostic insights and innovation and we focus on patients, growth and people to help achieve our goals. We offer high value diagnostic testing services and products attractive to patients, physicians, payers, and others and have become the provider of choice in key areas of the diagnostic testing market. We believe that successful execution of our strategy will drive continued growth of our business. Additionally, we believe that, over the long term, we will be able to grow at a rate above the U.S. clinical laboratory industry growth rate, to expand margins and to increase international revenues to 10% of consolidated revenues. The elements of our growth strategy are described below. - · Leverage our unparalleled assets and capabilities. We are the world leader in the clinical testing business and the leading cancer diagnostic testing provider. We offer the broadest test menu, with more than 3,000 tests, and are the leading provider in the United States of gene-based and esoteric testing. We have the most extensive clinical testing network in the United States, offering national access to testing services. We operate a nationwide network of over 2,000 of our own patient service centers where we collect patient specimens, and laboratories in most major metropolitan areas. We provide anatomic pathology services, including inpatient anatomic pathology and medical director services at hospitals, throughout the United States. We have a medical and scientific staff of approximately 900 M.D.s and Ph.D.s, primarily located in the United States, many of whom are recognized leaders in their field. We serve approximately half of the physicians and half of the hospitals in the United States. We also operate approximately 75 locations in the United States and Canada where we coordinate the provision of paramedical examinations related to life insurance applications. We have strong logistics capabilities, including approximately 3,200 courier vehicles and over 25 aircraft that collectively make approximately 80,000 stops daily. We have approximately 8,900 phlebotomists and a network of approximately 5,275 contracted paramedical examiners. We plan to continue to enhance our test menu and service capabilities. We believe that customers and payers prefer providers that offer a comprehensive and innovative range of tests and services and the most convenient access to those services and that, by offering such services, we will be able to profitably enhance our market position. - · Continue to lead in medical innovation and information technology solutions. We are a leading innovator in the clinical testing market with unmatched medical and technical expertise. We have the most comprehensive test menu and leading medical and scientific experts available for consultation. We collaborate with leading academic centers and maintain relationships with advisors and consultants that are leaders in key fields, such as cardiology, oncology and infectious disease. In connection with our research and development efforts, our medical and scientific experts publish in peer-reviewed journals research that demonstrates the clinical value and importance of diagnostic testing. In 2010, we published over thirty articles that support advancements and the latest thinking in laboratory testing and disease diagnosis. Over the past several years, we have expanded our business in more complex and faster-growing testing areas, including gene-based and esoteric testing, anatomic pathology services and point-of-care testing. We see significant opportunity to use diagnostics for personalized medicine. For example, our clinical trials business has biomarker capabilities that advance our efforts to develop companion diagnostics for new therapies that will foster personalized patient treatment. 1
[ { "bbox": [ 0.1038559807671441, 0.04278743739024585, 0.22177316339850228, 0.051732166821320244 ], "ocr": false, "ocr_confidence": 1, "text": "Item 1. Business" }, { "bbox": [ 0.13708778242171304, 0.06403211493753991, 0.8340101352773891, 0.07547063328144955 ], "ocr": false, "ocr_confidence": 1, "text": "Quest Diagnostics Incorporated is the world’s leading provider of diagnostic testing, information and" }, { "bbox": [ 0.10436814973998822, 0.07930937824273628, 0.8539253601782753, 0.09074789658664591 ], "ocr": false, "ocr_confidence": 1, "text": "services. We provide insights that enable patients, physicians and others to make better healthcare decisions." }, { "bbox": [ 0.13708778242171304, 0.10043822150882024, 0.8824488195416148, 0.11188944576648308 ], "ocr": false, "ocr_confidence": 1, "text": "Quest Diagnostics was incorporated in Delaware in 1990; its predecessor companies date back to 1967. We" }, { "bbox": [ 0.10393858825784813, 0.1157281907277698, 0.8822038691632981, 0.12716670907167943 ], "ocr": false, "ocr_confidence": 1, "text": "conduct business through our headquarters in Madison, New Jersey, and our laboratories, patient service centers," }, { "bbox": [ 0.10400467171993225, 0.13093296016922096, 0.8960622910836443, 0.13977588638948754 ], "ocr": false, "ocr_confidence": 1, "text": "offices and other facilities around the United States and in selected locations outside the United States. Unless the" }, { "bbox": [ 0.10393858825784813, 0.14621014552402617, 0.8233404713088205, 0.15764866386793583 ], "ocr": false, "ocr_confidence": 1, "text": "context otherwise requires, the terms “Quest Diagnostics,” the “Company,” “we” and “our” mean Quest" }, { "bbox": [ 0.1037898909788622, 0.16148740882922255, 0.502827557362925, 0.17292592717313218 ], "ocr": false, "ocr_confidence": 1, "text": "Diagnostics Incorporated and its consolidated subsidiaries." }, { "bbox": [ 0.1367903878637412, 0.1820691962503991, 0.8402999447748238, 0.19406755430336048 ], "ocr": false, "ocr_confidence": 1, "text": "During 2010, we generated net revenues of $7.4 billion and processed approximately 146 million test" }, { "bbox": [ 0.10360815196883422, 0.1979062992646472, 0.8128063904112252, 0.20934481760855683 ], "ocr": false, "ocr_confidence": 1, "text": "requisitions. Additional financial information concerning Quest Diagnostics, including our consolidated" }, { "bbox": [ 0.10436814973998822, 0.21318356256984355, 0.8598620666200248, 0.22462208091375319 ], "ocr": false, "ocr_confidence": 1, "text": "subsidiaries and business segments, for each of the years ended December 31, 2010, December 31, 2009 and" }, { "bbox": [ 0.1037898909788622, 0.22838825406090357, 0.894307555646248, 0.23884709188916825 ], "ocr": false, "ocr_confidence": 1, "text": "December 31, 2008 is included in the consolidated financial statements and notes thereto in “Financial Statements" }, { "bbox": [ 0.10413685129649604, 0.24366551736609993, 0.4078259823927239, 0.25510403571000956 ], "ocr": false, "ocr_confidence": 1, "text": "and Supplementary Data” in Part II, Item 8." }, { "bbox": [ 0.10410380323925619, 0.2799698207265725, 0.38587030565758446, 0.28899086359055715 ], "ocr": false, "ocr_confidence": 1, "text": "OUR STRATEGY AND STRENGTHS" }, { "bbox": [ 0.13708778242171304, 0.30122595698136173, 0.860134346172782, 0.3126644753252714 ], "ocr": false, "ocr_confidence": 1, "text": "Our mission is to be the undisputed world leader in diagnostic testing, information and services. We are" }, { "bbox": [ 0.10397162998889019, 0.3165032202865581, 0.8546903746242744, 0.32794173863046777 ], "ocr": false, "ocr_confidence": 1, "text": "dedicated to improving the health of patients through unsurpassed diagnostic insights and innovation and we" }, { "bbox": [ 0.1038559807671441, 0.33170791177761816, 0.5429720396228493, 0.3431464301215278 ], "ocr": false, "ocr_confidence": 1, "text": "focus on patients, growth and people to help achieve our goals." }, { "bbox": [ 0.1366086488537132, 0.3528495389078464, 0.8694559226977093, 0.36428805725175606 ], "ocr": false, "ocr_confidence": 1, "text": "We offer high value diagnostic testing services and products attractive to patients, physicians, payers, and" }, { "bbox": [ 0.10400467171993225, 0.3681268022130428, 0.8635442173896144, 0.3795653205569524 ], "ocr": false, "ocr_confidence": 1, "text": "others and have become the provider of choice in key areas of the diagnostic testing market. We believe that" }, { "bbox": [ 0.10436814973998822, 0.38340406551823913, 0.8719638299388475, 0.39484258386214877 ], "ocr": false, "ocr_confidence": 1, "text": "successful execution of our strategy will drive continued growth of our business. Additionally, we believe that," }, { "bbox": [ 0.10400467171993225, 0.3986813288234355, 0.880669285408893, 0.4101198471673451 ], "ocr": false, "ocr_confidence": 1, "text": "over the long term, we will be able to grow at a rate above the U.S. clinical laboratory industry growth rate, to" }, { "bbox": [ 0.10393858825784813, 0.41395859212863184, 0.8594800654928483, 0.42539711047254153 ], "ocr": false, "ocr_confidence": 1, "text": "expand margins and to increase international revenues to 10% of consolidated revenues. The elements of our" }, { "bbox": [ 0.1039881540175101, 0.42916332259488743, 0.35573789175865467, 0.4406018409387971 ], "ocr": false, "ocr_confidence": 1, "text": "growth strategy are described below." }, { "bbox": [ 0.13735212892244505, 0.4529768163064735, 0.1432999441675088, 0.4575700431034483 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1522216796875, 0.4503048717747246, 0.8882876470512023, 0.46174339011863424 ], "ocr": false, "ocr_confidence": 1, "text": "Leverage our unparalleled assets and capabilities. We are the world leader in the clinical testing business" }, { "bbox": [ 0.15293209904659644, 0.46558213507992097, 0.8887714746579602, 0.4770206534238306 ], "ocr": false, "ocr_confidence": 1, "text": "and the leading cancer diagnostic testing provider. We offer the broadest test menu, with more than 3,000" }, { "bbox": [ 0.1525355856216962, 0.48085935940992175, 0.8689866706506529, 0.49229787775383144 ], "ocr": false, "ocr_confidence": 1, "text": "tests, and are the leading provider in the United States of gene-based and esoteric testing. We have the" }, { "bbox": [ 0.1525851450551604, 0.49613662271511816, 0.8692509538894071, 0.5075751410590278 ], "ocr": false, "ocr_confidence": 1, "text": "most extensive clinical testing network in the United States, offering national access to testing services." }, { "bbox": [ 0.15240340604513242, 0.5114138470451189, 0.8501453304765236, 0.5228396594752753 ], "ocr": false, "ocr_confidence": 1, "text": "We operate a nationwide network of over 2,000 of our own patient service centers where we collect" }, { "bbox": [ 0.15240340604513242, 0.5266911103503152, 0.8573603337479271, 0.538129628694225 ], "ocr": false, "ocr_confidence": 1, "text": "patient specimens, and laboratories in most major metropolitan areas. We provide anatomic pathology" }, { "bbox": [ 0.1531634101424842, 0.5418958408165708, 0.8840280409476057, 0.5533343591604806 ], "ocr": false, "ocr_confidence": 1, "text": "services, including inpatient anatomic pathology and medical director services at hospitals, throughout the" }, { "bbox": [ 0.15255209699792055, 0.5571730651465717, 0.8750550632255389, 0.5686115834904814 ], "ocr": false, "ocr_confidence": 1, "text": "United States. We have a medical and scientific staff of approximately 900 M.D.s and Ph.D.s, primarily" }, { "bbox": [ 0.15263471714102017, 0.572450328451768, 0.8885219694172367, 0.5838888467956777 ], "ocr": false, "ocr_confidence": 1, "text": "located in the United States, many of whom are recognized leaders in their field. We serve approximately" }, { "bbox": [ 0.15246948950721653, 0.5876639062874162, 0.8659880528995647, 0.5991660711256784 ], "ocr": false, "ocr_confidence": 1, "text": "half of the physicians and half of the hospitals in the United States. We also operate approximately 75" }, { "bbox": [ 0.15263471714102017, 0.6030048160869652, 0.8890059994623238, 0.6144306285171216 ], "ocr": false, "ocr_confidence": 1, "text": "locations in the United States and Canada where we coordinate the provision of paramedical examinations" }, { "bbox": [ 0.15240340604513242, 0.618282040416966, 0.8836944225811049, 0.6297205587608756 ], "ocr": false, "ocr_confidence": 1, "text": "related to life insurance applications. We have strong logistics capabilities, including approximately 3,200" }, { "bbox": [ 0.15273383600794854, 0.6334956572278098, 0.8666408152920294, 0.644997822066072 ], "ocr": false, "ocr_confidence": 1, "text": "courier vehicles and over 25 aircraft that collectively make approximately 80,000 stops daily. We have" }, { "bbox": [ 0.15293209904659644, 0.6487728815578105, 0.8248026833605411, 0.6602750463960728 ], "ocr": false, "ocr_confidence": 1, "text": "approximately 8,900 phlebotomists and a network of approximately 5,275 contracted paramedical" }, { "bbox": [ 0.15273383600794854, 0.6640412585184188, 0.8386246663816335, 0.6754670514609774 ], "ocr": false, "ocr_confidence": 1, "text": "examiners. We plan to continue to enhance our test menu and service capabilities. We believe that" }, { "bbox": [ 0.15273383600794854, 0.6793185023360173, 0.8412467488404333, 0.6907570401675247 ], "ocr": false, "ocr_confidence": 1, "text": "customers and payers prefer providers that offer a comprehensive and innovative range of tests and" }, { "bbox": [ 0.1531634101424842, 0.6945957266660181, 0.8786352862963827, 0.7060342644975255 ], "ocr": false, "ocr_confidence": 1, "text": "services and the most convenient access to those services and that, by offering such services, we will be" }, { "bbox": [ 0.15293209904659644, 0.7098729899712145, 0.4757434345201078, 0.7213115278027219 ], "ocr": false, "ocr_confidence": 1, "text": "able to profitably enhance our market position." }, { "bbox": [ 0.13735211627004948, 0.7336865031703983, 0.14329993151511325, 0.7382797299673731 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1534112326145963, 0.7310145391510516, 0.8835425938342143, 0.742453076982559 ], "ocr": false, "ocr_confidence": 1, "text": "Continue to lead in medical innovation and information technology solutions. We are a leading innovator" }, { "bbox": [ 0.1525851450551604, 0.746291802456248, 0.8246177559468284, 0.7577303402877554 ], "ocr": false, "ocr_confidence": 1, "text": "in the clinical testing market with unmatched medical and technical expertise. We have the most" }, { "bbox": [ 0.15273383600794854, 0.7615689878110532, 0.8349669094307111, 0.7730075256425607 ], "ocr": false, "ocr_confidence": 1, "text": "comprehensive test menu and leading medical and scientific experts available for consultation. We" }, { "bbox": [ 0.15273383600794854, 0.7767737572525044, 0.8923814561631944, 0.7882122950840118 ], "ocr": false, "ocr_confidence": 1, "text": "collaborate with leading academic centers and maintain relationships with advisors and consultants that are" }, { "bbox": [ 0.15263471714102017, 0.7920510205577007, 0.888424495361733, 0.8034895583892082 ], "ocr": false, "ocr_confidence": 1, "text": "leaders in key fields, such as cardiology, oncology and infectious disease. In connection with our research" }, { "bbox": [ 0.15293209904659644, 0.807328205912506, 0.8901492699264096, 0.8187667437440134 ], "ocr": false, "ocr_confidence": 1, "text": "and development efforts, our medical and scientific experts publish in peer-reviewed journals research that" }, { "bbox": [ 0.15276688406518837, 0.8226054692177024, 0.8634650640029021, 0.8340440070492098 ], "ocr": false, "ocr_confidence": 1, "text": "demonstrates the clinical value and importance of diagnostic testing. In 2010, we published over thirty" }, { "bbox": [ 0.15293209904659644, 0.8378827325228987, 0.8901129322463205, 0.8493212800982051 ], "ocr": false, "ocr_confidence": 1, "text": "articles that support advancements and the latest thinking in laboratory testing and disease diagnosis. Over" }, { "bbox": [ 0.1525355856216962, 0.8531599958280951, 0.8807732374909307, 0.8645985434034014 ], "ocr": false, "ocr_confidence": 1, "text": "the past several years, we have expanded our business in more complex and faster-growing testing areas," }, { "bbox": [ 0.1525851450551604, 0.8684371811829003, 0.8158809225357587, 0.8798757287582066 ], "ocr": false, "ocr_confidence": 1, "text": "including gene-based and esoteric testing, anatomic pathology services and point-of-care testing." }, { "bbox": [ 0.15240340604513242, 0.8895074837052502, 0.8589316600590796, 0.9009460312805565 ], "ocr": false, "ocr_confidence": 1, "text": "We see significant opportunity to use diagnostics for personalized medicine. For example, our clinical" }, { "bbox": [ 0.1525355856216962, 0.9047847470104466, 0.8683770276223052, 0.9162232945857529 ], "ocr": false, "ocr_confidence": 1, "text": "trials business has biomarker capabilities that advance our efforts to develop companion diagnostics for" }, { "bbox": [ 0.1525851450551604, 0.9200620151875424, 0.5679909372408789, 0.9314878324895983 ], "ocr": false, "ocr_confidence": 1, "text": "new therapies that will foster personalized patient treatment." }, { "bbox": [ 0.49769584693718905, 0.9507055270413025, 0.502371514416848, 0.9593066998672972 ], "ocr": false, "ocr_confidence": 1, "text": "1" } ]
[ { "bbox": [ 0.10249395038358014, 0.04238006864623244, 0.22248979508382566, 0.05352853358477012 ], "data": [], "index_in_doc": 51, "label": "section_header", "text": "Item 1. Business" }, { "bbox": [ 0.102385494048718, 0.06251964349856322, 0.8539253601782753, 0.09074789658664591 ], "data": [], "index_in_doc": 52, "label": "text", "text": "Quest Diagnostics Incorporated is the world's leading provider of diagnostic testing, information and services. We provide insights that enable patients, physicians and others to make better healthcare decisions." }, { "bbox": [ 0.10167702948473777, 0.09893323330739144, 0.8962002528049855, 0.17350720323974297 ], "data": [], "index_in_doc": 53, "label": "text", "text": "Quest Diagnostics was incorporated in Delaware in 1990; its predecessor companies date back to 1967. We conduct business through our headquarters in Madison, New Jersey, and our laboratories, patient service centers, offices and other facilities around the United States and in selected locations outside the United States. Unless the context otherwise requires, the terms \"Quest Diagnostics,\" the \"Company,\" \"we\" and \"our\" mean Quest Diagnostics Incorporated and its consolidated subsidiaries." }, { "bbox": [ 0.10232115029102534, 0.1817156912266523, 0.8950116361551617, 0.2560567453903257 ], "data": [], "index_in_doc": 54, "label": "text", "text": "During 2010, we generated net revenues of $7.4 billion and processed approximately 146 million test requisitions. Additional financial information concerning Quest Diagnostics, including our consolidated subsidiaries and business segments, for each of the years ended December 31, 2010, December 31, 2009 and December 31, 2008 is included in the consolidated financial statements and notes thereto in \"Financial Statements and Supplementary Data\" in Part II, Item 8." }, { "bbox": [ 0.10247375083404592, 0.2790268548451469, 0.38678211319703565, 0.2891463746208493 ], "data": [], "index_in_doc": 55, "label": "section_header", "text": "OUR STRATEGY AND STRENGTHS" }, { "bbox": [ 0.10228922829699161, 0.2999883386214879, 0.861401104017672, 0.3435800681473499 ], "data": [], "index_in_doc": 56, "label": "text", "text": "Our mission is to be the undisputed world leader in diagnostic testing, information and services. We are dedicated to improving the health of patients through unsurpassed diagnostic insights and innovation and we focus on patients, growth and people to help achieve our goals." }, { "bbox": [ 0.10175877661254276, 0.35196285320881227, 0.8812957308185634, 0.4408887763285241 ], "data": [], "index_in_doc": 57, "label": "text", "text": "We offer high value diagnostic testing services and products attractive to patients, physicians, payers, and others and have become the provider of choice in key areas of the diagnostic testing market. We believe that successful execution of our strategy will drive continued growth of our business. Additionally, we believe that, over the long term, we will be able to grow at a rate above the U.S. clinical laboratory industry growth rate, to expand margins and to increase international revenues to 10% of consolidated revenues. The elements of our growth strategy are described below." }, { "bbox": [ 0.13510301378038195, 0.44894116865720785, 0.8905444295449834, 0.7213115278027219 ], "data": [], "index_in_doc": 58, "label": "text", "text": "- · Leverage our unparalleled assets and capabilities. We are the world leader in the clinical testing business and the leading cancer diagnostic testing provider. We offer the broadest test menu, with more than 3,000 tests, and are the leading provider in the United States of gene-based and esoteric testing. We have the most extensive clinical testing network in the United States, offering national access to testing services. We operate a nationwide network of over 2,000 of our own patient service centers where we collect patient specimens, and laboratories in most major metropolitan areas. We provide anatomic pathology services, including inpatient anatomic pathology and medical director services at hospitals, throughout the United States. We have a medical and scientific staff of approximately 900 M.D.s and Ph.D.s, primarily located in the United States, many of whom are recognized leaders in their field. We serve approximately half of the physicians and half of the hospitals in the United States. We also operate approximately 75 locations in the United States and Canada where we coordinate the provision of paramedical examinations related to life insurance applications. We have strong logistics capabilities, including approximately 3,200 courier vehicles and over 25 aircraft that collectively make approximately 80,000 stops daily. We have approximately 8,900 phlebotomists and a network of approximately 5,275 contracted paramedical examiners. We plan to continue to enhance our test menu and service capabilities. We believe that customers and payers prefer providers that offer a comprehensive and innovative range of tests and services and the most convenient access to those services and that, by offering such services, we will be able to profitably enhance our market position." }, { "bbox": [ 0.1354575718615581, 0.7302745755757104, 0.8923814561631944, 0.8805158476263171 ], "data": [], "index_in_doc": 59, "label": "text", "text": "- · Continue to lead in medical innovation and information technology solutions. We are a leading innovator in the clinical testing market with unmatched medical and technical expertise. We have the most comprehensive test menu and leading medical and scientific experts available for consultation. We collaborate with leading academic centers and maintain relationships with advisors and consultants that are leaders in key fields, such as cardiology, oncology and infectious disease. In connection with our research and development efforts, our medical and scientific experts publish in peer-reviewed journals research that demonstrates the clinical value and importance of diagnostic testing. In 2010, we published over thirty articles that support advancements and the latest thinking in laboratory testing and disease diagnosis. Over the past several years, we have expanded our business in more complex and faster-growing testing areas, including gene-based and esoteric testing, anatomic pathology services and point-of-care testing." }, { "bbox": [ 0.15086608937328333, 0.8880468687639687, 0.869235771014718, 0.9316352464230124 ], "data": [], "index_in_doc": 60, "label": "text", "text": "We see significant opportunity to use diagnostics for personalized medicine. For example, our clinical trials business has biomarker capabilities that advance our efforts to develop companion diagnostics for new therapies that will foster personalized patient treatment." }, { "bbox": [ 0.4961352498574834, 0.9497743024375399, 0.5027781118010209, 0.9594318102450511 ], "data": [], "index_in_doc": 61, "label": "page_footer", "text": "1" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 3 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-4
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
We remain a leading innovator in the clinical testing industry by continuing to introduce new tests, technology and services, including in personalized and targeted medicine. For example, in 2010, we introduced our XSense Fragile X with Reflex test. This test, which bypasses the need to perform the Southern Blot DNA analysis method in 99% of cases, enables patients to get their results more quickly than other tests and is a good example of our strength in new laboratory analysis techniques. In addition, as an industry leader with the largest and broadest U.S. network and expanding presence outside the United States, we believe we are the channel of choice for developers of new tests to introduce their products to the marketplace. Through our relationships with the academic medical community and pharmaceutical and biotechnology firms, we believe that we are a leader in bringing technical innovation to the market. We empower healthcare organizations and clinicians with information technology solutions that can help improve patient care and medical practice, through our Care360 TM suite of products, our Centergy Data Exchange and the ChartMaxx electronic document management system for hospitals. We provide interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly IT implementation or significant workflow disruption. These solutions offer access to a large national healthcare provider network, including approximately 160,000 networked physicians using Quest Diagnostics' Care360 connectivity products. The Care360 products, including our Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. Our Care360 EHR product allows physicians to generate a complete record of a clinical patient encounter, automates and streamlines the clinician's workflow, and allows for rapid deployment and implementation with minimal workflow disruption. We believe that these products enhance the value we provide to our customers and result in increased customer loyalty by providing more convenient ordering and reporting of clinical tests, greater convenience in electronically prescribing medication and better access to clinical information. In December 2010, the Care360 EHR solution received ONC-ATCB 2011/12 certification as a Complete EHR from the Certification Commission for Health Information Technology. The 2011/2012 criteria support the Stage 1 Meaningful Use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act, which included laws designed to expedite the implementation of electronic health records and build a national electronic health infrastructure in the United States. We believe that we are well positioned to enable physicians to participate in this government stimulus program. - · Deliver a superior patient experience. The patient is at the center of everything we do. Increasingly, patients have a choice when it comes to selecting a healthcare provider and we strive to give patients compelling reasons to put their trust in us. We have made significant investments in training our employees to provide a superior patient experience. We believe that this will drive patient and physician loyalty. We are a leader in providing patients with advanced tools to manage their healthcare and medical information. Our automated patient appointment scheduling enables patients to schedule appointments, including via mobile devices, at times that are convenient for them while essentially eliminating their waiting time. We believe that we are the only national clinical test provider that offers this service in almost all of its patient service centers. We also offer TestMinder TM , which sends email reminders to patients that require frequent testing. In 2010, we introduced Gazelle TM , a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results and manage their personal health information directly from their smartphone. We also collaborate with Keas TM , Microsoft HealthVault TM and Google Health TM in connection with their personal health records offerings. - · Continuously drive Six Sigma quality. We strive to provide the highest quality in all that we do, including: phlebotomy and specimen transport services; analytical testing processes in our laboratories; accurate and timely lab reports; and accurate and timely billing. We use Six Sigma and Lean processes to continuously reduce defects, enhance quality and further increase the efficiency of our operations. Six Sigma is a management approach that utilizes a thorough understanding of customer needs and requirements, root cause analysis, process improvements and rigorous tracking and measuring to enhance quality. Lean is a management approach that seeks to streamline processes and eliminate waste. We also use Six Sigma and Lean principles to help standardize operations and processes across our Company and identify and adopt company best practices. We believe our focus on continuously using Six Sigma and Lean in all aspects of our business results in superior service to our customers and drives customer loyalty. - · Expand our diagnostic scope. Technology advances are enabling testing to move closer to the patient and point-of-care, or near patient, tests are becoming increasingly available and reliable. This enables more 2
[ { "bbox": [ 0.15240368439783505, 0.0428169805884818, 0.8415510136492019, 0.05425549893239144 ], "ocr": false, "ocr_confidence": 1, "text": "We remain a leading innovator in the clinical testing industry by continuing to introduce new tests," }, { "bbox": [ 0.15253586397439883, 0.05802175002993295, 0.845005826175114, 0.06946026837384259 ], "ocr": false, "ocr_confidence": 1, "text": "technology and services, including in personalized and targeted medicine. For example, in 2010, we" }, { "bbox": [ 0.15258542340786302, 0.07292991823315773, 0.8609065471794672, 0.08473745372864783 ], "ocr": false, "ocr_confidence": 1, "text": "introduced our XSense\u0001 Fragile X with Reflex test. This test, which bypasses the need to perform the" }, { "bbox": [ 0.15301498489000312, 0.08857619868993455, 0.8698013837064676, 0.1000147170338442 ], "ocr": false, "ocr_confidence": 1, "text": "Southern Blot DNA analysis method in 99% of cases, enables patients to get their results more quickly" }, { "bbox": [ 0.15253586397439883, 0.1038534619951309, 0.8827825391272802, 0.11529198033904055 ], "ocr": false, "ocr_confidence": 1, "text": "than other tests and is a good example of our strength in new laboratory analysis techniques. In addition," }, { "bbox": [ 0.15293237739929907, 0.11913072530032727, 0.8491526741293532, 0.13056924364423692 ], "ocr": false, "ocr_confidence": 1, "text": "as an industry leader with the largest and broadest U.S. network and expanding presence outside the" }, { "bbox": [ 0.1525523753506232, 0.13440798860552364, 0.8540693950494921, 0.14583380103568008 ], "ocr": false, "ocr_confidence": 1, "text": "United States, we believe we are the channel of choice for developers of new tests to introduce their" }, { "bbox": [ 0.15240368439783505, 0.14968525191072, 0.8331629814793221, 0.16112377025462962 ], "ocr": false, "ocr_confidence": 1, "text": "products to the marketplace. Through our relationships with the academic medical community and" }, { "bbox": [ 0.15240368439783505, 0.16496251521591634, 0.8811634373704395, 0.17640103355982598 ], "ocr": false, "ocr_confidence": 1, "text": "pharmaceutical and biotechnology firms, we believe that we are a leader in bringing technical innovation" }, { "bbox": [ 0.15253586397439883, 0.18016720670697636, 0.2474597785405654, 0.18897193723559227 ], "ocr": false, "ocr_confidence": 1, "text": "to the market." }, { "bbox": [ 0.15240368439783505, 0.20297432189395753, 0.8765656580379353, 0.21441284023786716 ], "ocr": false, "ocr_confidence": 1, "text": "We empower healthcare organizations and clinicians with information technology solutions that can help" }, { "bbox": [ 0.15258542340786302, 0.2182388792854007, 0.594487027346989, 0.22969010354306355 ], "ocr": false, "ocr_confidence": 1, "text": "improve patient care and medical practice, through our Care360" }, { "bbox": [ 0.5951378159657442, 0.2177159880617417, 0.6105748013675114, 0.22310641350874041 ], "ocr": false, "ocr_confidence": 1, "text": "TM " }, { "bbox": [ 0.6180828847299958, 0.2182536119093231, 0.8694675629016376, 0.22969213025323276 ], "ocr": false, "ocr_confidence": 1, "text": "suite of products, our Centergy Data" }, { "bbox": [ 0.15252050396617176, 0.23353087521451948, 0.3561937322664024, 0.24496939355842912 ], "ocr": false, "ocr_confidence": 1, "text": "Exchange and the ChartMaxx" }, { "bbox": [ 0.3572841663265703, 0.23316185806293901, 0.3651485158436334, 0.2392182916517002 ], "ocr": false, "ocr_confidence": 1, "text": "\u0001 " }, { "bbox": [ 0.37264275748535963, 0.23353087521451948, 0.8344035235605824, 0.24496939355842912 ], "ocr": false, "ocr_confidence": 1, "text": "electronic document management system for hospitals. We provide" }, { "bbox": [ 0.15258658742825584, 0.24880813851971584, 0.8929692358519901, 0.26024665686362547 ], "ocr": false, "ocr_confidence": 1, "text": "interoperable technologies that help healthcare organizations and physicians enter, share and access clinical" }, { "bbox": [ 0.15258658742825584, 0.2640854018249122, 0.8621795806125622, 0.2755239201688218 ], "ocr": false, "ocr_confidence": 1, "text": "information without costly IT implementation or significant workflow disruption. These solutions offer" }, { "bbox": [ 0.1529335414196919, 0.279277387402219, 0.8370518217830121, 0.29072861165988184 ], "ocr": false, "ocr_confidence": 1, "text": "access to a large national healthcare provider network, including approximately 160,000 networked" }, { "bbox": [ 0.15240484841822788, 0.2945546507074154, 0.8779068119688018, 0.30600587496507825 ], "ocr": false, "ocr_confidence": 1, "text": "physicians using Quest Diagnostics’ Care360 connectivity products. The Care360 products, including our" }, { "bbox": [ 0.15278485046690377, 0.30983191401261173, 0.8791206321906094, 0.3212831382702746 ], "ocr": false, "ocr_confidence": 1, "text": "Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results" }, { "bbox": [ 0.15265267089033996, 0.3251091773178081, 0.8523260973776948, 0.33656040157547096 ], "ocr": false, "ocr_confidence": 1, "text": "from Quest Diagnostics and electronically to prescribe medication. Our Care360 EHR product allows" }, { "bbox": [ 0.15240484841822788, 0.3403991465367577, 0.8637258045708955, 0.3518376648806673 ], "ocr": false, "ocr_confidence": 1, "text": "physicians to generate a complete record of a clinical patient encounter, automates and streamlines the" }, { "bbox": [ 0.152735278381044, 0.35567640984195403, 0.8361165060925839, 0.36711492818586366 ], "ocr": false, "ocr_confidence": 1, "text": "clinician’s workflow, and allows for rapid deployment and implementation with minimal workflow" }, { "bbox": [ 0.15276832643828384, 0.3709536731471504, 0.8694424605488185, 0.38237948557730683 ], "ocr": false, "ocr_confidence": 1, "text": "disruption. We believe that these products enhance the value we provide to our customers and result in" }, { "bbox": [ 0.15258658742825584, 0.38623093645234674, 0.8763748599126762, 0.39766945479625637 ], "ocr": false, "ocr_confidence": 1, "text": "increased customer loyalty by providing more convenient ordering and reporting of clinical tests, greater" }, { "bbox": [ 0.152735278381044, 0.40143562794340676, 0.798617234870569, 0.4128741462873164 ], "ocr": false, "ocr_confidence": 1, "text": "convenience in electronically prescribing medication and better access to clinical information." }, { "bbox": [ 0.1526196354854957, 0.4242299982414392, 0.8782137084758499, 0.4356685555605444 ], "ocr": false, "ocr_confidence": 1, "text": "In December 2010, the Care360 EHR solution received ONC-ATCB 2011/12 certification as a Complete" }, { "bbox": [ 0.15252050396617176, 0.4395200064355843, 0.8456910293098311, 0.45095852477949394 ], "ocr": false, "ocr_confidence": 1, "text": "EHR from the Certification Commission for Health Information Technology. The 2011/2012 criteria" }, { "bbox": [ 0.15316485251557965, 0.45479726974078066, 0.8513578348491916, 0.4662357880846903 ], "ocr": false, "ocr_confidence": 1, "text": "support the Stage 1 Meaningful Use measures required to qualify eligible providers and hospitals for" }, { "bbox": [ 0.15265267089033996, 0.470074533045977, 0.8728625549012748, 0.48151305138988665 ], "ocr": false, "ocr_confidence": 1, "text": "funding under the American Recovery and Reinvestment Act, which included laws designed to expedite" }, { "bbox": [ 0.15253702799479166, 0.4852793024874282, 0.8828052122201493, 0.4967051149175846 ], "ocr": false, "ocr_confidence": 1, "text": "the implementation of electronic health records and build a national electronic health infrastructure in the" }, { "bbox": [ 0.152553539371016, 0.5005565657926245, 0.8161549228143139, 0.5119950841365342 ], "ocr": false, "ocr_confidence": 1, "text": "United States. We believe that we are well positioned to enable physicians to participate in this" }, { "bbox": [ 0.15278485046690377, 0.5158338290978208, 0.3595575487633447, 0.5272723474417306 ], "ocr": false, "ocr_confidence": 1, "text": "government stimulus program." }, { "bbox": [ 0.1373535839479361, 0.5413128888165509, 0.14330139919299983, 0.5459061156135258 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15222310940819989, 0.538640944284802, 0.8495390276806074, 0.5500794626287117 ], "ocr": false, "ocr_confidence": 1, "text": "Deliver a superior patient experience. The patient is at the center of everything we do. Increasingly," }, { "bbox": [ 0.15240484841822788, 0.5539182075899984, 0.8589643538492434, 0.5653567259339081 ], "ocr": false, "ocr_confidence": 1, "text": "patients have a choice when it comes to selecting a healthcare provider and we strive to give patients" }, { "bbox": [ 0.152735278381044, 0.5691954708951947, 0.8247892718212324, 0.5806339892391044 ], "ocr": false, "ocr_confidence": 1, "text": "compelling reasons to put their trust in us. We have made significant investments in training our" }, { "bbox": [ 0.152735278381044, 0.5844002013614503, 0.8782568278399668, 0.59583871970536 ], "ocr": false, "ocr_confidence": 1, "text": "employees to provide a superior patient experience. We believe that this will drive patient and physician" }, { "bbox": [ 0.15263615951411563, 0.5996774646666467, 0.8893478165811567, 0.6111159830105564 ], "ocr": false, "ocr_confidence": 1, "text": "loyalty. We are a leader in providing patients with advanced tools to manage their healthcare and medical" }, { "bbox": [ 0.15258658742825584, 0.614954727971843, 0.8586488537132048, 0.6263932463157527 ], "ocr": false, "ocr_confidence": 1, "text": "information. Our automated patient appointment scheduling enables patients to schedule appointments," }, { "bbox": [ 0.15258658742825584, 0.6302319912770394, 0.8568874378109452, 0.6416705096209491 ], "ocr": false, "ocr_confidence": 1, "text": "including via mobile devices, at times that are convenient for them while essentially eliminating their" }, { "bbox": [ 0.1526691949189599, 0.6455092545822357, 0.85919563964034, 0.6569477729261455 ], "ocr": false, "ocr_confidence": 1, "text": "waiting time. We believe that we are the only national clinical test provider that offers this service in" }, { "bbox": [ 0.1529335414196919, 0.6607864789122366, 0.6094866447385469, 0.672212291342393 ], "ocr": false, "ocr_confidence": 1, "text": "almost all of its patient service centers. We also offer TestMinder" }, { "bbox": [ 0.6097105921402104, 0.6602535320881227, 0.6251475775419776, 0.6656439575351213 ], "ocr": false, "ocr_confidence": 1, "text": "TM" }, { "bbox": [ 0.6262510688743781, 0.6607912338860952, 0.8543483550671124, 0.6712500327391643 ], "ocr": false, "ocr_confidence": 1, "text": ", which sends email reminders to" }, { "bbox": [ 0.15240469658948097, 0.6760684777036937, 0.6288103448415475, 0.6875070155352011 ], "ocr": false, "ocr_confidence": 1, "text": "patients that require frequent testing. In 2010, we introduced Gazelle" }, { "bbox": [ 0.6294544023858571, 0.6755308928313078, 0.6448913877876243, 0.6809213377659044 ], "ocr": false, "ocr_confidence": 1, "text": "TM" }, { "bbox": [ 0.6459949803391895, 0.676068633604476, 0.8747779251528814, 0.6874944460346324 ], "ocr": false, "ocr_confidence": 1, "text": ", a secure mobile health platform" }, { "bbox": [ 0.15253738226186775, 0.6913458969096723, 0.8662210594164593, 0.7027844347411798 ], "ocr": false, "ocr_confidence": 1, "text": "that allows users to receive their Quest Diagnostics laboratory results and manage their personal health" }, { "bbox": [ 0.15258694169533193, 0.7065506273759279, 0.6687043096691024, 0.7179891652074354 ], "ocr": false, "ocr_confidence": 1, "text": "information directly from their smartphone. We also collaborate with Keas" }, { "bbox": [ 0.6695061172814314, 0.7060858091936562, 0.6849431026831986, 0.7114762541282527 ], "ocr": false, "ocr_confidence": 1, "text": "TM" }, { "bbox": [ 0.6861405760099243, 0.7061820389514987, 0.8574460663803379, 0.7170098354685505 ], "ocr": false, "ocr_confidence": 1, "text": ", Microsoft\u0001 HealthVault" }, { "bbox": [ 0.857730289794517, 0.7060858091936562, 0.8731673258058665, 0.7114762541282527 ], "ocr": false, "ocr_confidence": 1, "text": "TM" }, { "bbox": [ 0.15293237739929907, 0.7218283973586666, 0.2818398293768786, 0.733266935190174 ], "ocr": false, "ocr_confidence": 1, "text": "and Google Health" }, { "bbox": [ 0.2822457435316905, 0.7213631894244392, 0.29768277954304, 0.7267536343590357 ], "ocr": false, "ocr_confidence": 1, "text": "TM " }, { "bbox": [ 0.3046126231229918, 0.7218283973586666, 0.7030323844643968, 0.733266935190174 ], "ocr": false, "ocr_confidence": 1, "text": "in connection with their personal health records offerings." }, { "bbox": [ 0.13735328029044233, 0.7473074570773967, 0.14330109553550607, 0.7519006838743714 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15341239663498912, 0.74463549305805, 0.8937194722999585, 0.7560740308895574 ], "ocr": false, "ocr_confidence": 1, "text": "Continuously drive Six Sigma quality. We strive to provide the highest quality in all that we do, including:" }, { "bbox": [ 0.15240457006552524, 0.7599127563632463, 0.8813923951207504, 0.7713512941947538 ], "ocr": false, "ocr_confidence": 1, "text": "phlebotomy and specimen transport services; analytical testing processes in our laboratories; accurate and" }, { "bbox": [ 0.15253674964208905, 0.7751900196684427, 0.889696010507359, 0.7866285574999501 ], "ocr": false, "ocr_confidence": 1, "text": "timely lab reports; and accurate and timely billing. We use Six Sigma and Lean processes to continuously" }, { "bbox": [ 0.15240457006552524, 0.7903947501346983, 0.846321675314832, 0.8018332879662057 ], "ocr": false, "ocr_confidence": 1, "text": "reduce defects, enhance quality and further increase the efficiency of our operations. Six Sigma is a" }, { "bbox": [ 0.15258630907555323, 0.8056720134398946, 0.8623626860813122, 0.8171105512714021 ], "ocr": false, "ocr_confidence": 1, "text": "management approach that utilizes a thorough understanding of customer needs and requirements, root" }, { "bbox": [ 0.15273500002834137, 0.8209492572574932, 0.8764060354153711, 0.8323877950890006 ], "ocr": false, "ocr_confidence": 1, "text": "cause analysis, process improvements and rigorous tracking and measuring to enhance quality. Lean is a" }, { "bbox": [ 0.15258630907555323, 0.8362265400502874, 0.8880688112173507, 0.8476650778817948 ], "ocr": false, "ocr_confidence": 1, "text": "management approach that seeks to streamline processes and eliminate waste. We also use Six Sigma and" }, { "bbox": [ 0.15252022561346912, 0.8515037838678859, 0.8781442721289386, 0.8629423314431922 ], "ocr": false, "ocr_confidence": 1, "text": "Lean principles to help standardize operations and processes across our Company and identify and adopt" }, { "bbox": [ 0.15273500002834137, 0.8667810374292834, 0.8924369242653918, 0.8782195850045897 ], "ocr": false, "ocr_confidence": 1, "text": "company best practices. We believe our focus on continuously using Six Sigma and Lean in all aspects of" }, { "bbox": [ 0.15280109614282106, 0.8820583007344798, 0.7409727688057111, 0.893496848309786 ], "ocr": false, "ocr_confidence": 1, "text": "our business results in superior service to our customers and drives customer loyalty." }, { "bbox": [ 0.13735328029044233, 0.9074648373580679, 0.14330109553550607, 0.9120580641550428 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1523219625748212, 0.9047928733387213, 0.886188867673352, 0.9162314209140275 ], "ocr": false, "ocr_confidence": 1, "text": "Expand our diagnostic scope. Technology advances are enabling testing to move closer to the patient and" }, { "bbox": [ 0.15240457006552524, 0.9200701415158171, 0.8653613038324005, 0.9315086793473245 ], "ocr": false, "ocr_confidence": 1, "text": "point-of-care, or near patient, tests are becoming increasingly available and reliable. This enables more" }, { "bbox": [ 0.4963588429920709, 0.9507137313199683, 0.5037109982314988, 0.959314904145963 ], "ocr": false, "ocr_confidence": 1, "text": "2" } ]
[ { "bbox": [ 0.15104884057495724, 0.042291672902697953, 0.8841389771520004, 0.18983632912276502 ], "data": [], "index_in_doc": 62, "label": "text", "text": "We remain a leading innovator in the clinical testing industry by continuing to introduce new tests, technology and services, including in personalized and targeted medicine. For example, in 2010, we introduced our XSense Fragile X with Reflex test. This test, which bypasses the need to perform the Southern Blot DNA analysis method in 99% of cases, enables patients to get their results more quickly than other tests and is a good example of our strength in new laboratory analysis techniques. In addition, as an industry leader with the largest and broadest U.S. network and expanding presence outside the United States, we believe we are the channel of choice for developers of new tests to introduce their products to the marketplace. Through our relationships with the academic medical community and pharmaceutical and biotechnology firms, we believe that we are a leader in bringing technical innovation to the market." }, { "bbox": [ 0.1507364276234388, 0.20252478198834611, 0.89334293700767, 0.4131067892296256 ], "data": [], "index_in_doc": 63, "label": "text", "text": "We empower healthcare organizations and clinicians with information technology solutions that can help improve patient care and medical practice, through our Care360 TM suite of products, our Centergy Data Exchange and the ChartMaxx electronic document management system for hospitals. We provide interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly IT implementation or significant workflow disruption. These solutions offer access to a large national healthcare provider network, including approximately 160,000 networked physicians using Quest Diagnostics' Care360 connectivity products. The Care360 products, including our Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. Our Care360 EHR product allows physicians to generate a complete record of a clinical patient encounter, automates and streamlines the clinician's workflow, and allows for rapid deployment and implementation with minimal workflow disruption. We believe that these products enhance the value we provide to our customers and result in increased customer loyalty by providing more convenient ordering and reporting of clinical tests, greater convenience in electronically prescribing medication and better access to clinical information." }, { "bbox": [ 0.150919735530518, 0.42346542183010055, 0.8829170593970253, 0.5275906968390804 ], "data": [], "index_in_doc": 64, "label": "text", "text": "In December 2010, the Care360 EHR solution received ONC-ATCB 2011/12 certification as a Complete EHR from the Certification Commission for Health Information Technology. The 2011/2012 criteria support the Stage 1 Meaningful Use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act, which included laws designed to expedite the implementation of electronic health records and build a national electronic health infrastructure in the United States. We believe that we are well positioned to enable physicians to participate in this government stimulus program." }, { "bbox": [ 0.135527969790533, 0.5374328301479685, 0.8896113912857587, 0.733266935190174 ], "data": [], "index_in_doc": 65, "label": "text", "text": "- · Deliver a superior patient experience. The patient is at the center of everything we do. Increasingly, patients have a choice when it comes to selecting a healthcare provider and we strive to give patients compelling reasons to put their trust in us. We have made significant investments in training our employees to provide a superior patient experience. We believe that this will drive patient and physician loyalty. We are a leader in providing patients with advanced tools to manage their healthcare and medical information. Our automated patient appointment scheduling enables patients to schedule appointments, including via mobile devices, at times that are convenient for them while essentially eliminating their waiting time. We believe that we are the only national clinical test provider that offers this service in almost all of its patient service centers. We also offer TestMinder TM , which sends email reminders to patients that require frequent testing. In 2010, we introduced Gazelle TM , a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results and manage their personal health information directly from their smartphone. We also collaborate with Keas TM , Microsoft HealthVault TM and Google Health TM in connection with their personal health records offerings." }, { "bbox": [ 0.1355358648853713, 0.7435328458004071, 0.8944554368457193, 0.8944561058229565 ], "data": [], "index_in_doc": 66, "label": "text", "text": "- · Continuously drive Six Sigma quality. We strive to provide the highest quality in all that we do, including: phlebotomy and specimen transport services; analytical testing processes in our laboratories; accurate and timely lab reports; and accurate and timely billing. We use Six Sigma and Lean processes to continuously reduce defects, enhance quality and further increase the efficiency of our operations. Six Sigma is a management approach that utilizes a thorough understanding of customer needs and requirements, root cause analysis, process improvements and rigorous tracking and measuring to enhance quality. Lean is a management approach that seeks to streamline processes and eliminate waste. We also use Six Sigma and Lean principles to help standardize operations and processes across our Company and identify and adopt company best practices. We believe our focus on continuously using Six Sigma and Lean in all aspects of our business results in superior service to our customers and drives customer loyalty." }, { "bbox": [ 0.13543090061168767, 0.9036425594169061, 0.8861908920566438, 0.9319411237577826 ], "data": [], "index_in_doc": 67, "label": "text", "text": "- · Expand our diagnostic scope. Technology advances are enabling testing to move closer to the patient and point-of-care, or near patient, tests are becoming increasingly available and reliable. This enables more" }, { "bbox": [ 0.49496540936269173, 0.9496713299708652, 0.50387385986733, 0.9594279127254949 ], "data": [], "index_in_doc": 68, "label": "page_footer", "text": "2" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 4 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-5
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
timely and effective decisions, with the opportunity to improve patient care and reduce medical costs. We have three businesses that offer point-of-care testing: HemoCue, Focus Diagnostics and Enterix. We intend to expand our product menus, develop novel technology platforms and systems to meet the needs of our clients and pursue potential additional acquisitions to supplement our offering. Test results from our pointof-care products can be entered into our Care360 system, enabling the integration of tests performed in a near patient setting with those performed in our laboratories. We are well positioned to offer choice and integrated solutions to physicians, hospitals, clinics and retail customers for the testing methods that are most appropriate for each patient and practice. - · Expand our geographic reach. In addition to growth opportunities in the United States, we see opportunities to expand our presence in India, Ireland, Mexico, Puerto Rico and the U.K. and to bring our experience and expertise in diagnostic testing to other international markets, particularly to developing countries where the testing markets are highly fragmented and less mature. To support our strategy, we expect to continue to selectively evaluate acquisitions in the United States and in select international markets. We anticipate that acquisitions will enable us to expand our capabilities, further leverage our assets and differentiate our Company from our competition, diversify our revenues and accelerate our growth. BUSINESS OPERATIONS Quest Diagnostics is the world's leading provider of diagnostic testing, information and services, providing insights that enable patients, physicians and others to make better healthcare decisions. We offer U.S. patients and physicians the broadest access to diagnostic testing services through our nationwide network of laboratories and Company-owned patient service centers. We provide interpretive consultation through the largest medical and scientific staff in the industry, with approximately 900 M.D.s and Ph.D.s, primarily located in the United States, many of whom are recognized leaders in their field. We are the leading provider of clinical testing, including gene-based and esoteric testing, anatomic pathology services and testing for drugs-of-abuse, and the leading provider of risk assessment services for the life insurance industry. We also are a leading provider of testing for clinical trials. Our diagnostics products business manufactures and markets FDA cleared or approved diagnostic test kits and specialized point-of-care testing. We empower healthcare organizations and clinicians with robust information technology solutions. Our activities are described below. Patients are at the center of everything that we do. We are leveraging our diagnostic testing capabilities and our assets to serve multiple customer bases. Most of our services are provided in the United States; for each of the years ended December 31, 2008, 2009 and 2010, we derived approximately 3% of our revenues from foreign operations and held approximately 7% of our long-lived assets outside the United States. The following chart shows the percentage of our 2010 net revenues generated by the activities identified. Clinical Testing. We are the world's largest commercial clinical testing company. Clinical testing is an essential element in the delivery of healthcare services. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. We offer customers the broadest access to the most extensive test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples. Clinical laboratory tests which can be performed by most clinical laboratories are considered routine. Esoteric tests are clinical laboratory tests that are not routine, require highly skilled personnel and generally require more sophisticated equipment. Anatomic pathology services are performed on tissues, such as biopsies, and other samples, such as human cells. As tests increasingly become more complex, we believe that providing sound medical and scientific consultation regarding our tests and test results will help spur the integration of new tests into clinical practice, and help physicians best utilize these tests to improve patient outcomes and enhance patient satisfaction. To this end, our in-house experts, including 3
[ { "bbox": [ 0.15253586397439883, 0.0428169805884818, 0.8878100950326493, 0.05425549893239144 ], "ocr": false, "ocr_confidence": 1, "text": "timely and effective decisions, with the opportunity to improve patient care and reduce medical costs. We" }, { "bbox": [ 0.15246976785991914, 0.05802175002993295, 0.8927335976368159, 0.06946026837384259 ], "ocr": false, "ocr_confidence": 1, "text": "have three businesses that offer point-of-care testing: HemoCue, Focus Diagnostics and Enterix. We intend" }, { "bbox": [ 0.15253586397439883, 0.07329893538473818, 0.877621272705483, 0.08473745372864783 ], "ocr": false, "ocr_confidence": 1, "text": "to expand our product menus, develop novel technology platforms and systems to meet the needs of our" }, { "bbox": [ 0.15273411436065118, 0.08857619868993455, 0.8909576061748549, 0.1000147170338442 ], "ocr": false, "ocr_confidence": 1, "text": "clients and pursue potential additional acquisitions to supplement our offering. Test results from our point\u0002" }, { "bbox": [ 0.15280021047513084, 0.10384075608137772, 0.8825199766143242, 0.11529198033904055 ], "ocr": false, "ocr_confidence": 1, "text": "of-care products can be entered into our Care360 system, enabling the integration of tests performed in a" }, { "bbox": [ 0.15258542340786302, 0.11913072530032727, 0.8770727660525498, 0.13056924364423692 ], "ocr": false, "ocr_confidence": 1, "text": "near patient setting with those performed in our laboratories. We are well positioned to offer choice and" }, { "bbox": [ 0.15258542340786302, 0.13440798860552364, 0.8717940853998238, 0.14584650694943327 ], "ocr": false, "ocr_confidence": 1, "text": "integrated solutions to physicians, hospitals, clinics and retail customers for the testing methods that are" }, { "bbox": [ 0.15258542340786302, 0.14968525191072, 0.47312175693796643, 0.16111106434087644 ], "ocr": false, "ocr_confidence": 1, "text": "most appropriate for each patient and practice." }, { "bbox": [ 0.13735239462275212, 0.1738614098170099, 0.14330020986781586, 0.17845463661398467 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.152321076907131, 0.17118942631006545, 0.8103219660162728, 0.18262794465397508 ], "ocr": false, "ocr_confidence": 1, "text": "Expand our geographic reach. In addition to growth opportunities in the United States, we see" }, { "bbox": [ 0.15280021047513084, 0.1864666896152618, 0.8912549880804311, 0.19790520795917146 ], "ocr": false, "ocr_confidence": 1, "text": "opportunities to expand our presence in India, Ireland, Mexico, Puerto Rico and the U.K. and to bring our" }, { "bbox": [ 0.15273411436065118, 0.20174395292045819, 0.8607195953824627, 0.21318247126436782 ], "ocr": false, "ocr_confidence": 1, "text": "experience and expertise in diagnostic testing to other international markets, particularly to developing" }, { "bbox": [ 0.15273411436065118, 0.21702121622565454, 0.6708175127779074, 0.22845973456956417 ], "ocr": false, "ocr_confidence": 1, "text": "countries where the testing markets are highly fragmented and less mature." }, { "bbox": [ 0.13680717759266817, 0.238525390625, 0.8788568550476783, 0.24996390896890963 ], "ocr": false, "ocr_confidence": 1, "text": "To support our strategy, we expect to continue to selectively evaluate acquisitions in the United States and" }, { "bbox": [ 0.10379015667916926, 0.2538027318805875, 0.874609395243833, 0.26522854431074394 ], "ocr": false, "ocr_confidence": 1, "text": "in select international markets. We anticipate that acquisitions will enable us to expand our capabilities, further" }, { "bbox": [ 0.10383972243883123, 0.2690799172353927, 0.8692991342117538, 0.28051843557930234 ], "ocr": false, "ocr_confidence": 1, "text": "leverage our assets and differentiate our Company from our competition, diversify our revenues and accelerate" }, { "bbox": [ 0.1040049374202393, 0.28428468667684387, 0.18169834522860956, 0.2957232050207535 ], "ocr": false, "ocr_confidence": 1, "text": "our growth." }, { "bbox": [ 0.10379015667916926, 0.32102418707096103, 0.29783946680983103, 0.3300452299349457 ], "ocr": false, "ocr_confidence": 1, "text": "BUSINESS OPERATIONS" }, { "bbox": [ 0.1370880481220201, 0.3426428705948675, 0.8773039506244817, 0.35408138893877716 ], "ocr": false, "ocr_confidence": 1, "text": "Quest Diagnostics is the world’s leading provider of diagnostic testing, information and services, providing" }, { "bbox": [ 0.10379015667916926, 0.35792013390006383, 0.8659204384976161, 0.3693586522439735 ], "ocr": false, "ocr_confidence": 1, "text": "insights that enable patients, physicians and others to make better healthcare decisions. We offer U.S. patients" }, { "bbox": [ 0.1041371169968031, 0.37319739720526024, 0.8773385675787728, 0.38463591554916987 ], "ocr": false, "ocr_confidence": 1, "text": "and physicians the broadest access to diagnostic testing services through our nationwide network of laboratories" }, { "bbox": [ 0.1041371169968031, 0.38840212767151583, 0.8919206053067993, 0.39984064601542546 ], "ocr": false, "ocr_confidence": 1, "text": "and Company-owned patient service centers. We provide interpretive consultation through the largest medical and" }, { "bbox": [ 0.10436841544029526, 0.4036793909767122, 0.8821527534851783, 0.4151179093206218 ], "ocr": false, "ocr_confidence": 1, "text": "scientific staff in the industry, with approximately 900 M.D.s and Ph.D.s, primarily located in the United States," }, { "bbox": [ 0.10379015667916926, 0.41895665428190854, 0.8645705797185945, 0.43039517262581817 ], "ocr": false, "ocr_confidence": 1, "text": "many of whom are recognized leaders in their field. We are the leading provider of clinical testing, including" }, { "bbox": [ 0.10398841971781717, 0.43423395656230046, 0.8491890118094424, 0.4456724749062101 ], "ocr": false, "ocr_confidence": 1, "text": "gene-based and esoteric testing, anatomic pathology services and testing for drugs-of-abuse, and the leading" }, { "bbox": [ 0.10360841766914128, 0.4495112198674968, 0.8839837069535137, 0.46094973821140645 ], "ocr": false, "ocr_confidence": 1, "text": "provider of risk assessment services for the life insurance industry. We also are a leading provider of testing for" }, { "bbox": [ 0.10393885395815519, 0.4647884441974976, 0.8759888100189158, 0.47622696254140723 ], "ocr": false, "ocr_confidence": 1, "text": "clinical trials. Our diagnostics products business manufactures and markets FDA cleared or approved diagnostic" }, { "bbox": [ 0.10374059091950728, 0.48006570750269395, 0.8672023792171952, 0.4915042258466036 ], "ocr": false, "ocr_confidence": 1, "text": "test kits and specialized point-of-care testing. We empower healthcare organizations and clinicians with robust" }, { "bbox": [ 0.10379015667916926, 0.4953429318326948, 0.577149297862899, 0.5067814501766044 ], "ocr": false, "ocr_confidence": 1, "text": "information technology solutions. Our activities are described below." }, { "bbox": [ 0.13679065356404824, 0.5168471452072357, 0.8883502004949212, 0.5282856635511455 ], "ocr": false, "ocr_confidence": 1, "text": "Patients are at the center of everything that we do. We are leveraging our diagnostic testing capabilities and" }, { "bbox": [ 0.1040049374202393, 0.5321244085124321, 0.8790849018255079, 0.5435502209425886 ], "ocr": false, "ocr_confidence": 1, "text": "our assets to serve multiple customer bases. Most of our services are provided in the United States; for each of" }, { "bbox": [ 0.10374059091950728, 0.5474016328424329, 0.8889370692112355, 0.5588401511863426 ], "ocr": false, "ocr_confidence": 1, "text": "the years ended December 31, 2008, 2009 and 2010, we derived approximately 3% of our revenues from foreign" }, { "bbox": [ 0.1040049374202393, 0.5626063633086885, 0.8620063946219424, 0.5740448816525981 ], "ocr": false, "ocr_confidence": 1, "text": "operations and held approximately 7% of our long-lived assets outside the United States. The following chart" }, { "bbox": [ 0.10436841544029526, 0.5778836266138849, 0.6899610933775134, 0.5893221449577946 ], "ocr": false, "ocr_confidence": 1, "text": "shows the percentage of our 2010 net revenues generated by the activities identified." }, { "bbox": [ 0.13664482205265988, 0.6086510747176325, 0.18110875624724684, 0.6177511592782168 ], "ocr": false, "ocr_confidence": 1, "text": "Activity" }, { "bbox": [ 0.7209688759166407, 0.5984414832649865, 0.8631503736201803, 0.6075517403516124 ], "ocr": false, "ocr_confidence": 1, "text": "Approximate Percentage" }, { "bbox": [ 0.729359387956053, 0.6086510747176325, 0.8548893715018657, 0.6158476886773627 ], "ocr": false, "ocr_confidence": 1, "text": "of 2010 Net Revenues" }, { "bbox": [ 0.13698847376885107, 0.626036974053121, 0.813237533442812, 0.6374754923970306 ], "ocr": false, "ocr_confidence": 1, "text": "Clinical testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91%" }, { "bbox": [ 0.16990140342396093, 0.6412505908639647, 0.8132292334713153, 0.652752755702227 ], "ocr": false, "ocr_confidence": 1, "text": "Routine clinical testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52%" }, { "bbox": [ 0.16986835536672107, 0.6565915006635137, 0.8132292334713153, 0.6680300190074234 ], "ocr": false, "ocr_confidence": 1, "text": "Anatomic pathology testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14%" }, { "bbox": [ 0.170149225896073, 0.6718687249935146, 0.8132275633550995, 0.683307262825022 ], "ocr": false, "ocr_confidence": 1, "text": "Gene-based and esoteric testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22%" }, { "bbox": [ 0.169884879395341, 0.6871459882987109, 0.8131400593873083, 0.6985845261302183 ], "ocr": false, "ocr_confidence": 1, "text": "Drugs of abuse testing (employer services). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3%" }, { "bbox": [ 0.1368397828160629, 0.7024232516039073, 0.6982497789373445, 0.7138617894354147 ], "ocr": false, "ocr_confidence": 1, "text": "Healthcare information technology, clinical trials testing, life insurer services and" }, { "bbox": [ 0.15351846166708774, 0.7151659579417106, 0.8131515477624897, 0.726604495773218 ], "ocr": false, "ocr_confidence": 1, "text": "diagnostic products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9%" }, { "bbox": [ 0.13733377029646687, 0.7367859666222661, 0.8563906541511194, 0.7483262881769835 ], "ocr": false, "ocr_confidence": 1, "text": "Clinical Testing. We are the world’s largest commercial clinical testing company. Clinical testing is an" }, { "bbox": [ 0.10393677263908323, 0.7521649941630747, 0.8605122985333747, 0.7636035319945821 ], "ocr": false, "ocr_confidence": 1, "text": "essential element in the delivery of healthcare services. Physicians use clinical tests to assist in the detection," }, { "bbox": [ 0.10396981437012529, 0.7673697246293303, 0.8463978933457711, 0.7788082624608377 ], "ocr": false, "ocr_confidence": 1, "text": "diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is" }, { "bbox": [ 0.1039863383987452, 0.7826469684469288, 0.8514057115140443, 0.7940855062784363 ], "ocr": false, "ocr_confidence": 1, "text": "generally categorized as clinical laboratory testing and anatomic pathology services. We offer customers the" }, { "bbox": [ 0.10357329461902726, 0.7979242317521252, 0.8887215736098155, 0.8093627695836326 ], "ocr": false, "ocr_confidence": 1, "text": "broadest access to the most extensive test menu of clinical laboratory and anatomic pathology tests in the United" }, { "bbox": [ 0.10421764316843517, 0.8132014950573216, 0.8726659872836339, 0.824640032888829 ], "ocr": false, "ocr_confidence": 1, "text": "States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids," }, { "bbox": [ 0.10436633412122331, 0.8284787583625179, 0.8868101509056281, 0.8399173059378243 ], "ocr": false, "ocr_confidence": 1, "text": "such as urine, and specimens such as microbiology samples. Clinical laboratory tests which can be performed by" }, { "bbox": [ 0.1037880753600973, 0.8437560021801166, 0.8699199113482069, 0.8551945497554229 ], "ocr": false, "ocr_confidence": 1, "text": "most clinical laboratories are considered routine. Esoteric tests are clinical laboratory tests that are not routine," }, { "bbox": [ 0.10360633635006931, 0.8590332654853129, 0.8902747816905058, 0.8704718130606192 ], "ocr": false, "ocr_confidence": 1, "text": "require highly skilled personnel and generally require more sophisticated equipment. Anatomic pathology services" }, { "bbox": [ 0.10413503567773114, 0.8743105482781071, 0.8882457423170605, 0.8857490958534133 ], "ocr": false, "ocr_confidence": 1, "text": "are performed on tissues, such as biopsies, and other samples, such as human cells. As tests increasingly become" }, { "bbox": [ 0.1037880753600973, 0.8895152787443626, 0.8716017689870957, 0.9009538263196689 ], "ocr": false, "ocr_confidence": 1, "text": "more complex, we believe that providing sound medical and scientific consultation regarding our tests and test" }, { "bbox": [ 0.10360633635006931, 0.904792542049559, 0.8932797762489635, 0.9162310896248653 ], "ocr": false, "ocr_confidence": 1, "text": "results will help spur the integration of new tests into clinical practice, and help physicians best utilize these tests" }, { "bbox": [ 0.10373850960043532, 0.9200698102266548, 0.8370187231161899, 0.9315083480581622 ], "ocr": false, "ocr_confidence": 1, "text": "to improve patient outcomes and enhance patient satisfaction. To this end, our in-house experts, including" }, { "bbox": [ 0.4965706440939832, 0.9507133805432082, 0.5029810562260313, 0.9594672362618671 ], "ocr": false, "ocr_confidence": 1, "text": "3" } ]
[ { "bbox": [ 0.15057331293969606, 0.04237274130946679, 0.8927335976368159, 0.16162779748363665 ], "data": [], "index_in_doc": 69, "label": "text", "text": "timely and effective decisions, with the opportunity to improve patient care and reduce medical costs. We have three businesses that offer point-of-care testing: HemoCue, Focus Diagnostics and Enterix. We intend to expand our product menus, develop novel technology platforms and systems to meet the needs of our clients and pursue potential additional acquisitions to supplement our offering. Test results from our pointof-care products can be entered into our Care360 system, enabling the integration of tests performed in a near patient setting with those performed in our laboratories. We are well positioned to offer choice and integrated solutions to physicians, hospitals, clinics and retail customers for the testing methods that are most appropriate for each patient and practice." }, { "bbox": [ 0.1354005095575184, 0.16967921543243136, 0.8920679804104478, 0.2287326388888889 ], "data": [], "index_in_doc": 70, "label": "text", "text": "- · Expand our geographic reach. In addition to growth opportunities in the United States, we see opportunities to expand our presence in India, Ireland, Mexico, Puerto Rico and the U.K. and to bring our experience and expertise in diagnostic testing to other international markets, particularly to developing countries where the testing markets are highly fragmented and less mature." }, { "bbox": [ 0.10228353471898322, 0.23703872076548532, 0.8800211790979996, 0.2960724227729885 ], "data": [], "index_in_doc": 71, "label": "text", "text": "To support our strategy, we expect to continue to selectively evaluate acquisitions in the United States and in select international markets. We anticipate that acquisitions will enable us to expand our capabilities, further leverage our assets and differentiate our Company from our competition, diversify our revenues and accelerate our growth." }, { "bbox": [ 0.10273108158143203, 0.3206783991359355, 0.2981835360550762, 0.33059633920019155 ], "data": [], "index_in_doc": 72, "label": "section_header", "text": "BUSINESS OPERATIONS" }, { "bbox": [ 0.10201477885839358, 0.34171931436083175, 0.8924111133784204, 0.5069781579886056 ], "data": [], "index_in_doc": 73, "label": "text", "text": "Quest Diagnostics is the world's leading provider of diagnostic testing, information and services, providing insights that enable patients, physicians and others to make better healthcare decisions. We offer U.S. patients and physicians the broadest access to diagnostic testing services through our nationwide network of laboratories and Company-owned patient service centers. We provide interpretive consultation through the largest medical and scientific staff in the industry, with approximately 900 M.D.s and Ph.D.s, primarily located in the United States, many of whom are recognized leaders in their field. We are the leading provider of clinical testing, including gene-based and esoteric testing, anatomic pathology services and testing for drugs-of-abuse, and the leading provider of risk assessment services for the life insurance industry. We also are a leading provider of testing for clinical trials. Our diagnostics products business manufactures and markets FDA cleared or approved diagnostic test kits and specialized point-of-care testing. We empower healthcare organizations and clinicians with robust information technology solutions. Our activities are described below." }, { "bbox": [ 0.10228648905334979, 0.5161432142001916, 0.8895941840277778, 0.5897537562734475 ], "data": [], "index_in_doc": 74, "label": "text", "text": "Patients are at the center of everything that we do. We are leveraging our diagnostic testing capabilities and our assets to serve multiple customer bases. Most of our services are provided in the United States; for each of the years ended December 31, 2008, 2009 and 2010, we derived approximately 3% of our revenues from foreign operations and held approximately 7% of our long-lived assets outside the United States. The following chart shows the percentage of our 2010 net revenues generated by the activities identified." }, { "bbox": [ 0.13490686369179494, 0.5973828390031329, 0.8636946290682007, 0.7277015111151022 ], "data": [ { "html_seq": "<table><tr><th>Activity of 2010 Net Revenues</th></tr><tr><td>Clinical testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91%</td></tr><tr><td>Routine clinical testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52%</td></tr><tr><td>Anatomic pathology testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14%</td></tr><tr><td>Gene-based and esoteric testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22%</td></tr><tr><td>Drugs of abuse testing (employer services). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3%</td></tr><tr><td>Healthcare information technology, clinical trials testing, life insurer services and diagnostic products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9%</td></tr></table>", "otsl_seq": "" } ], "index_in_doc": 75, "label": "table", "text": "" }, { "bbox": [ 0.10209202805957193, 0.7357770157347542, 0.8932797762489635, 0.931539991045059 ], "data": [], "index_in_doc": 76, "label": "text", "text": "Clinical Testing. We are the world's largest commercial clinical testing company. Clinical testing is an essential element in the delivery of healthcare services. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. We offer customers the broadest access to the most extensive test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples. Clinical laboratory tests which can be performed by most clinical laboratories are considered routine. Esoteric tests are clinical laboratory tests that are not routine, require highly skilled personnel and generally require more sophisticated equipment. Anatomic pathology services are performed on tissues, such as biopsies, and other samples, such as human cells. As tests increasingly become more complex, we believe that providing sound medical and scientific consultation regarding our tests and test results will help spur the integration of new tests into clinical practice, and help physicians best utilize these tests to improve patient outcomes and enhance patient satisfaction. To this end, our in-house experts, including" }, { "bbox": [ 0.49459945147310325, 0.9496564414461606, 0.5037305335302653, 0.9600243891183748 ], "data": [], "index_in_doc": 77, "label": "page_footer", "text": "3" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 5 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-6
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
medical directors, scientific directors, genetic counselors and board certified geneticists are available for consultation with our customers regarding testing that we perform. Routine clinical testing. We are the leading provider of routine clinical testing, including testing for drugsof-abuse. We perform routine testing through our network of major laboratories and rapid response laboratories. Rapid response laboratories are smaller facilities where we can quickly perform an abbreviated menu of routine tests for customers that require rapid turnaround times. We also perform routine testing at hospital laboratories that we manage. We operate laboratories 24 hours a day, 365 days a year, performing and reporting most routine tests within 24 hours. The majority of test results are delivered electronically. Routine tests measure various important bodily health parameters such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include: - · blood chemistries, including cholesterol levels; - · complete blood cell counts; - · urinalyses; - · pregnancy and other prenatal tests; - · routine microbiology testing; - · prescription drug monitoring; - · alcohol and other substance-abuse tests; and - · allergy tests such as the ImmunoCap test. Anatomic pathology testing. We are the leading provider of anatomic pathology services in the United States, through our AmeriPath TM , Dermpath Diagnostics TM and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. We provide inpatient anatomic pathology and medical director services at hospitals throughout the country, and through our major laboratories. We provide a full range of services to all anatomic pathology subspecialties. We have approximately 725 medical doctors, including luminaries in their field, with a passion for providing the highest quality service to patients. Among them are approximately 700 pathologists. We provide integrated, comprehensive reports that include both anatomic pathology and clinical pathology tests, enabling our pathologists to offer patients and physicians a complete analysis. Our approach fosters personalized patient care. We have a strong history of leadership and innovation in cancer diagnostics. We introduced the Leumeta family of tests for leukemia and lymphoma. These proprietary plasma-based molecular tests may some day eliminate the need for painful bone marrow biopsies. As discussed below under the heading "Scientific Innovation," recently we introduced our Lung Cancer Mutation Panel, designed to aid treatment selection for lung cancer patients. This panel detects mutations in the EFGR, ALK and KRAS genes. This panel, together with our numerous individual tests for lung cancer mutations, provides the most comprehensive lung cancer test offerings available from a commercial laboratory. Gene-Based and Esoteric Testing. We are the leading provider in the United States of gene-based and esoteric testing. Gene-based and esoteric tests increasingly are ordered by physicians to assist them in the diagnostic process, to establish a prognosis and to choose or monitor a therapeutic regimen. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, autoimmune panels and complex cancer evaluations. Esoteric tests typically require professional "hands-on" attention from highly-skilled technical personnel, generally require more sophisticated technology, equipment or materials and may be performed less frequently than routine tests. Consequently, esoteric tests are generally reimbursed at higher levels than routine tests. It is not practical, from a cost-effectiveness or infrastructure perspective, for most hospitals, commercial laboratories or physician office laboratories to develop and perform a broad menu of esoteric tests, or to perform low-volume esoteric testing in-house. Such tests generally are outsourced to an esoteric clinical testing laboratory, which specializes in performing these complex tests. We conduct complex and specialized testing, including molecular diagnostics, in our world renowned Quest Diagnostics Nichols Institute laboratory facilities, and in a number of other locations, including Focus Diagnostics. Our esoteric laboratories provide reference testing services to physicians, large academic medical centers, hospitals and other commercial laboratories. Our esoteric testing laboratories perform hundreds of complex tests that are not routinely performed by our regional laboratories, including but not limited to the following fields: 4
[ { "bbox": [ 0.1037898909788622, 0.04288924060105364, 0.8239054260760003, 0.054327758944963285 ], "ocr": false, "ocr_confidence": 1, "text": "medical directors, scientific directors, genetic counselors and board certified geneticists are available for" }, { "bbox": [ 0.10393858825784813, 0.05816650390625, 0.5627882721807629, 0.06960502225015965 ], "ocr": false, "ocr_confidence": 1, "text": "consultation with our customers regarding testing that we perform." }, { "bbox": [ 0.1363443023529812, 0.07901924688697318, 0.8770860257631116, 0.09045776523088282 ], "ocr": false, "ocr_confidence": 1, "text": "Routine clinical testing. We are the leading provider of routine clinical testing, including testing for drugs\u0002" }, { "bbox": [ 0.10400468437232781, 0.09429651019216954, 0.877648905537417, 0.10573502853607918 ], "ocr": false, "ocr_confidence": 1, "text": "of-abuse. We perform routine testing through our network of major laboratories and rapid response laboratories." }, { "bbox": [ 0.1038064276598777, 0.10950127963362069, 0.8781678561942889, 0.12093979797753034 ], "ocr": false, "ocr_confidence": 1, "text": "Rapid response laboratories are smaller facilities where we can quickly perform an abbreviated menu of routine" }, { "bbox": [ 0.1037403378715958, 0.12477854293881704, 0.8708517349774565, 0.1362170612827267 ], "ocr": false, "ocr_confidence": 1, "text": "tests for customers that require rapid turnaround times. We also perform routine testing at hospital laboratories" }, { "bbox": [ 0.1037403378715958, 0.13999219872485633, 0.8910448570947347, 0.15149432458792306 ], "ocr": false, "ocr_confidence": 1, "text": "that we manage. We operate laboratories 24 hours a day, 365 days a year, performing and reporting most routine" }, { "bbox": [ 0.1037403378715958, 0.15533299159881864, 0.6408881698279436, 0.1667715099427283 ], "ocr": false, "ocr_confidence": 1, "text": "tests within 24 hours. The majority of test results are delivered electronically." }, { "bbox": [ 0.13680692454475668, 0.17618581252993296, 0.8847253397724917, 0.1876243308738426 ], "ocr": false, "ocr_confidence": 1, "text": "Routine tests measure various important bodily health parameters such as the functions of the kidney, heart," }, { "bbox": [ 0.10383946939091974, 0.19139050402099297, 0.5500301025795502, 0.2028290223649026 ], "ocr": false, "ocr_confidence": 1, "text": "liver, thyroid and other organs. Commonly ordered tests include:" }, { "bbox": [ 0.13735214157484063, 0.2149152305086606, 0.14329995681990437, 0.21950845730563537 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1523703832926837, 0.21224324700171615, 0.47318754939495233, 0.2236817653456258 ], "ocr": false, "ocr_confidence": 1, "text": "blood chemistries, including cholesterol levels;" }, { "bbox": [ 0.13735214157484063, 0.23569547962563858, 0.14329995681990437, 0.24028870642261335 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1527338613127397, 0.23302349611869413, 0.3411691137411899, 0.24444930854885058 ], "ocr": false, "ocr_confidence": 1, "text": "complete blood cell counts;" }, { "bbox": [ 0.13735214157484063, 0.25654822260636173, 0.14329995681990437, 0.2611414494033365 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15246951481200768, 0.2538762390994173, 0.22300074942669465, 0.26531475744332694 ], "ocr": false, "ocr_confidence": 1, "text": "urinalyses;" }, { "bbox": [ 0.13735214157484063, 0.27732847172333974, 0.14329995681990437, 0.2819216985203145 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15240343134992357, 0.27465648821639527, 0.39160328322579807, 0.2860950065603049 ], "ocr": false, "ocr_confidence": 1, "text": "pregnancy and other prenatal tests;" }, { "bbox": [ 0.13735214157484063, 0.2981812147040629, 0.14329995681990437, 0.30277444150103766 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15240343134992357, 0.29550923119711847, 0.3493390945257437, 0.3069477495410281 ], "ocr": false, "ocr_confidence": 1, "text": "routine microbiology testing;" }, { "bbox": [ 0.13735214157484063, 0.31896146382104085, 0.14329995681990437, 0.3235546906180157 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15240343134992357, 0.3162894803140964, 0.3518916900280499, 0.32772799865800606 ], "ocr": false, "ocr_confidence": 1, "text": "prescription drug monitoring;" }, { "bbox": [ 0.13735214157484063, 0.33981420680176405, 0.14329995681990437, 0.3444074335987388 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1529321243513876, 0.33714222329481963, 0.45671868521973463, 0.34760102214788874 ], "ocr": false, "ocr_confidence": 1, "text": "alcohol and other substance-abuse tests; and" }, { "bbox": [ 0.13735214157484063, 0.3605943779683509, 0.14329995681990437, 0.3651876047653257 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1529321243513876, 0.357922433436602, 0.4066182353207919, 0.36936095178051165 ], "ocr": false, "ocr_confidence": 1, "text": "allergy tests such as the ImmunoCap" }, { "bbox": [ 0.40786396488423765, 0.3575534162850216, 0.4157283144013008, 0.36360988884897827 ], "ocr": false, "ocr_confidence": 1, "text": "\u0001 " }, { "bbox": [ 0.42293013387651585, 0.35924568030112547, 0.4487370479956986, 0.36672716396521793 ], "ocr": false, "ocr_confidence": 1, "text": "test." }, { "bbox": [ 0.1357164778321932, 0.37877517641732517, 0.8950383580146144, 0.39021369476123485 ], "ocr": false, "ocr_confidence": 1, "text": "Anatomic pathology testing. We are the leading provider of anatomic pathology services in the United States," }, { "bbox": [ 0.10374199533541602, 0.3940524786977171, 0.26132455196348986, 0.4054909970416268 ], "ocr": false, "ocr_confidence": 1, "text": "through our AmeriPath" }, { "bbox": [ 0.26174972306436567, 0.39351458202376677, 0.27718675907571516, 0.39890500747076546 ], "ocr": false, "ocr_confidence": 1, "text": "TM" }, { "bbox": [ 0.2783842577072321, 0.39405216689615263, 0.4381179429998445, 0.40549068524006227 ], "ocr": false, "ocr_confidence": 1, "text": ", Dermpath Diagnostics" }, { "bbox": [ 0.43897380164606653, 0.39351458202376677, 0.4544107870478338, 0.39890500747076546 ], "ocr": false, "ocr_confidence": 1, "text": "TM " }, { "bbox": [ 0.4616877364479685, 0.39405216689615263, 0.8755900065104166, 0.40549068524006227 ], "ocr": false, "ocr_confidence": 1, "text": "and Quest Diagnostics brands. Anatomic pathology involves" }, { "bbox": [ 0.10374123619168156, 0.409329430201349, 0.8897320445299544, 0.4207679485452586 ], "ocr": false, "ocr_confidence": 1, "text": "the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples" }, { "bbox": [ 0.10374123619168156, 0.42460669350654534, 0.8217287079414127, 0.436045211850455 ], "ocr": false, "ocr_confidence": 1, "text": "taken from patients. We provide inpatient anatomic pathology and medical director services at hospitals" }, { "bbox": [ 0.10374123619168156, 0.43981142397280093, 0.5134272282791771, 0.45124994231671056 ], "ocr": false, "ocr_confidence": 1, "text": "throughout the country, and through our major laboratories." }, { "bbox": [ 0.13660957247859012, 0.46060052045917144, 0.867946846172782, 0.47210268529743377 ], "ocr": false, "ocr_confidence": 1, "text": "We provide a full range of services to all anatomic pathology subspecialties. We have approximately 725" }, { "bbox": [ 0.10379080195134355, 0.4759414302587205, 0.8660929159540838, 0.4873799486026301 ], "ocr": false, "ocr_confidence": 1, "text": "medical doctors, including luminaries in their field, with a passion for providing the highest quality service to" }, { "bbox": [ 0.10360906294131556, 0.49121869356391684, 0.8595899895055971, 0.5026572119078264 ], "ocr": false, "ocr_confidence": 1, "text": "patients. Among them are approximately 700 pathologists. We provide integrated, comprehensive reports that" }, { "bbox": [ 0.10379080195134355, 0.5064959178939177, 0.8514034846924233, 0.5179344362378273 ], "ocr": false, "ocr_confidence": 1, "text": "include both anatomic pathology and clinical pathology tests, enabling our pathologists to offer patients and" }, { "bbox": [ 0.10360906294131556, 0.5217006873353688, 0.6471309124138422, 0.5331392056792784 ], "ocr": false, "ocr_confidence": 1, "text": "physicians a complete analysis. Our approach fosters personalized patient care." }, { "bbox": [ 0.13660957247859012, 0.5425534303160919, 0.8659261067708334, 0.5539919486600016 ], "ocr": false, "ocr_confidence": 1, "text": "We have a strong history of leadership and innovation in cancer diagnostics. We introduced the Leumeta" }, { "bbox": [ 0.8666714846989013, 0.5421844131645115, 0.8745358089111733, 0.5482408857284682 ], "ocr": false, "ocr_confidence": 1, "text": "\u0001" }, { "bbox": [ 0.10385686643483429, 0.5578306936212883, 0.845404427245284, 0.569269211965198 ], "ocr": false, "ocr_confidence": 1, "text": "family of tests for leukemia and lymphoma. These proprietary plasma-based molecular tests may some day" }, { "bbox": [ 0.10393947392553832, 0.5731079569264846, 0.8181451952477198, 0.5845464752703943 ], "ocr": false, "ocr_confidence": 1, "text": "eliminate the need for painful bone marrow biopsies. As discussed below under the heading “Scientific" }, { "bbox": [ 0.10382381837759445, 0.5883851812564854, 0.894649069107587, 0.5998236996003952 ], "ocr": false, "ocr_confidence": 1, "text": "Innovation,” recently we introduced our Lung Cancer Mutation Panel, designed to aid treatment selection for lung" }, { "bbox": [ 0.10393947392553832, 0.603589911722741, 0.8872125983040526, 0.6150284300666508 ], "ocr": false, "ocr_confidence": 1, "text": "cancer patients. This panel detects mutations in the EFGR, ALK and KRAS genes. This panel, together with our" }, { "bbox": [ 0.1037907766465524, 0.6188671750279374, 0.8816332967324834, 0.630305693371847 ], "ocr": false, "ocr_confidence": 1, "text": "numerous individual tests for lung cancer mutations, provides the most comprehensive lung cancer test offerings" }, { "bbox": [ 0.10413773696418623, 0.6341444383331338, 0.3783537451900653, 0.6455829566770435 ], "ocr": false, "ocr_confidence": 1, "text": "available from a commercial laboratory." }, { "bbox": [ 0.13738607529977068, 0.6549972202890525, 0.8451999645328048, 0.6664357386329621 ], "ocr": false, "ocr_confidence": 1, "text": "Gene-Based and Esoteric Testing. We are the leading provider in the United States of gene-based and" }, { "bbox": [ 0.10393949923032947, 0.6702744835942489, 0.835990184575171, 0.6817130214257563 ], "ocr": false, "ocr_confidence": 1, "text": "esoteric testing. Gene-based and esoteric tests increasingly are ordered by physicians to assist them in the" }, { "bbox": [ 0.10397254096137153, 0.6854792140605045, 0.8916120892931177, 0.6969177518920119 ], "ocr": false, "ocr_confidence": 1, "text": "diagnostic process, to establish a prognosis and to choose or monitor a therapeutic regimen. Esoteric tests include" }, { "bbox": [ 0.10360906294131556, 0.7007564773657008, 0.8167443726193252, 0.7121950151972083 ], "ocr": false, "ocr_confidence": 1, "text": "procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced" }, { "bbox": [ 0.10379080195134355, 0.7160337406708972, 0.8948621354490568, 0.7274722785024046 ], "ocr": false, "ocr_confidence": 1, "text": "microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring" }, { "bbox": [ 0.10374123619168156, 0.7313110234636914, 0.8879181971004353, 0.7427495612951988 ], "ocr": false, "ocr_confidence": 1, "text": "tests, autoimmune panels and complex cancer evaluations. Esoteric tests typically require professional “hands-on”" }, { "bbox": [ 0.10413776226897738, 0.7465882867688877, 0.8761314278218284, 0.7580268246003952 ], "ocr": false, "ocr_confidence": 1, "text": "attention from highly-skilled technical personnel, generally require more sophisticated technology, equipment or" }, { "bbox": [ 0.10379080195134355, 0.7618655500740841, 0.8513487251243781, 0.7733040879055915 ], "ocr": false, "ocr_confidence": 1, "text": "materials and may be performed less frequently than routine tests. Consequently, esoteric tests are generally" }, { "bbox": [ 0.10360906294131556, 0.7771428133792804, 0.8412822261576234, 0.7885813512107879 ], "ocr": false, "ocr_confidence": 1, "text": "reimbursed at higher levels than routine tests. It is not practical, from a cost-effectiveness or infrastructure" }, { "bbox": [ 0.10360906294131556, 0.7924200766844768, 0.8886286544167185, 0.8038586145159842 ], "ocr": false, "ocr_confidence": 1, "text": "perspective, for most hospitals, commercial laboratories or physician office laboratories to develop and perform a" }, { "bbox": [ 0.1035760212102735, 0.8076248071507324, 0.8344686580929985, 0.8190633449822398 ], "ocr": false, "ocr_confidence": 1, "text": "broad menu of esoteric tests, or to perform low-volume esoteric testing in-house. Such tests generally are" }, { "bbox": [ 0.10400558269241358, 0.8229020704559287, 0.8590397621268657, 0.8343406082874362 ], "ocr": false, "ocr_confidence": 1, "text": "outsourced to an esoteric clinical testing laboratory, which specializes in performing these complex tests. We" }, { "bbox": [ 0.10393949923032947, 0.8381792947859296, 0.8211837945688225, 0.8496178423612358 ], "ocr": false, "ocr_confidence": 1, "text": "conduct complex and specialized testing, including molecular diagnostics, in our world renowned Quest" }, { "bbox": [ 0.10379080195134355, 0.8534565580911259, 0.7629331269272129, 0.8648951056664322 ], "ocr": false, "ocr_confidence": 1, "text": "Diagnostics Nichols Institute laboratory facilities, and in a number of other locations, including" }, { "bbox": [ 0.10372471848925943, 0.8687337824211266, 0.23036869485579914, 0.880172329996433 ], "ocr": false, "ocr_confidence": 1, "text": "Focus Diagnostics." }, { "bbox": [ 0.13708870604658996, 0.8895140315381046, 0.8649083480708437, 0.900952579113411 ], "ocr": false, "ocr_confidence": 1, "text": "Our esoteric laboratories provide reference testing services to physicians, large academic medical centers," }, { "bbox": [ 0.10367515272959746, 0.904791294843301, 0.8781422477456468, 0.9162298424186073 ], "ocr": false, "ocr_confidence": 1, "text": "hospitals and other commercial laboratories. Our esoteric testing laboratories perform hundreds of complex tests" }, { "bbox": [ 0.10374123619168156, 0.9200685240452012, 0.8666694603156094, 0.9315070618767086 ], "ocr": false, "ocr_confidence": 1, "text": "that are not routinely performed by our regional laboratories, including but not limited to the following fields:" }, { "bbox": [ 0.4960611574290008, 0.9507121138493525, 0.5036611984025187, 0.9593132866753472 ], "ocr": false, "ocr_confidence": 1, "text": "4" } ]
[ { "bbox": [ 0.1020269378105404, 0.04236666117895913, 0.8242146000142516, 0.07029574066590837 ], "data": [], "index_in_doc": 78, "label": "text", "text": "medical directors, scientific directors, genetic counselors and board certified geneticists are available for consultation with our customers regarding testing that we perform." }, { "bbox": [ 0.10194274877038959, 0.07804642600574713, 0.8914566166563018, 0.16732963474317528 ], "data": [], "index_in_doc": 79, "label": "text", "text": "Routine clinical testing. We are the leading provider of routine clinical testing, including testing for drugsof-abuse. We perform routine testing through our network of major laboratories and rapid response laboratories. Rapid response laboratories are smaller facilities where we can quickly perform an abbreviated menu of routine tests for customers that require rapid turnaround times. We also perform routine testing at hospital laboratories that we manage. We operate laboratories 24 hours a day, 365 days a year, performing and reporting most routine tests within 24 hours. The majority of test results are delivered electronically." }, { "bbox": [ 0.10263293694896287, 0.1751552304088841, 0.8859969561372824, 0.2031792534722222 ], "data": [], "index_in_doc": 80, "label": "text", "text": "Routine tests measure various important bodily health parameters such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include:" }, { "bbox": [ 0.13561615698768528, 0.21152150433030012, 0.4741182090038091, 0.22432111445362388 ], "data": [], "index_in_doc": 81, "label": "text", "text": "- · blood chemistries, including cholesterol levels;" }, { "bbox": [ 0.1362780544097546, 0.23198379380188378, 0.3419229940790838, 0.24478831479984833 ], "data": [], "index_in_doc": 82, "label": "text", "text": "- · complete blood cell counts;" }, { "bbox": [ 0.13573415322881038, 0.2528373942369093, 0.22410153314644227, 0.26623511771132663 ], "data": [], "index_in_doc": 83, "label": "text", "text": "- · urinalyses;" }, { "bbox": [ 0.13589587614903995, 0.27407092487827267, 0.39258412223550215, 0.28693437637192687 ], "data": [], "index_in_doc": 84, "label": "text", "text": "- · pregnancy and other prenatal tests;" }, { "bbox": [ 0.13594284184141142, 0.2942015354356242, 0.3497498418956649, 0.30726282502195085 ], "data": [], "index_in_doc": 85, "label": "text", "text": "- · routine microbiology testing;" }, { "bbox": [ 0.13567219444768347, 0.31549828384418904, 0.352142333984375, 0.3283404548810664 ], "data": [], "index_in_doc": 86, "label": "text", "text": "- · prescription drug monitoring;" }, { "bbox": [ 0.135968083370582, 0.33589618629270435, 0.45671868521973463, 0.34760102214788874 ], "data": [], "index_in_doc": 87, "label": "text", "text": "- · alcohol and other substance-abuse tests; and" }, { "bbox": [ 0.1355764031607911, 0.3568192015510257, 0.44912345215653504, 0.37001113599287594 ], "data": [], "index_in_doc": 88, "label": "text", "text": "- · allergy tests such as the ImmunoCap test." }, { "bbox": [ 0.10233691517591081, 0.37745754198096265, 0.8959068184468284, 0.4518498875019955 ], "data": [], "index_in_doc": 89, "label": "text", "text": "Anatomic pathology testing. We are the leading provider of anatomic pathology services in the United States, through our AmeriPath TM , Dermpath Diagnostics TM and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. We provide inpatient anatomic pathology and medical director services at hospitals throughout the country, and through our major laboratories." }, { "bbox": [ 0.10245239991651443, 0.4590854376820921, 0.8688239102339863, 0.5337191955644357 ], "data": [], "index_in_doc": 90, "label": "text", "text": "We provide a full range of services to all anatomic pathology subspecialties. We have approximately 725 medical doctors, including luminaries in their field, with a passion for providing the highest quality service to patients. Among them are approximately 700 pathologists. We provide integrated, comprehensive reports that include both anatomic pathology and clinical pathology tests, enabling our pathologists to offer patients and physicians a complete analysis. Our approach fosters personalized patient care." }, { "bbox": [ 0.10175615756665889, 0.5417822670967034, 0.8951297589202425, 0.6455829566770435 ], "data": [], "index_in_doc": 91, "label": "text", "text": "We have a strong history of leadership and innovation in cancer diagnostics. We introduced the Leumeta family of tests for leukemia and lymphoma. These proprietary plasma-based molecular tests may some day eliminate the need for painful bone marrow biopsies. As discussed below under the heading \"Scientific Innovation,\" recently we introduced our Lung Cancer Mutation Panel, designed to aid treatment selection for lung cancer patients. This panel detects mutations in the EFGR, ALK and KRAS genes. This panel, together with our numerous individual tests for lung cancer mutations, provides the most comprehensive lung cancer test offerings available from a commercial laboratory." }, { "bbox": [ 0.10178205069420151, 0.6540865648447478, 0.894871548831364, 0.880172329996433 ], "data": [], "index_in_doc": 92, "label": "text", "text": "Gene-Based and Esoteric Testing. We are the leading provider in the United States of gene-based and esoteric testing. Gene-based and esoteric tests increasingly are ordered by physicians to assist them in the diagnostic process, to establish a prognosis and to choose or monitor a therapeutic regimen. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, autoimmune panels and complex cancer evaluations. Esoteric tests typically require professional \"hands-on\" attention from highly-skilled technical personnel, generally require more sophisticated technology, equipment or materials and may be performed less frequently than routine tests. Consequently, esoteric tests are generally reimbursed at higher levels than routine tests. It is not practical, from a cost-effectiveness or infrastructure perspective, for most hospitals, commercial laboratories or physician office laboratories to develop and perform a broad menu of esoteric tests, or to perform low-volume esoteric testing in-house. Such tests generally are outsourced to an esoteric clinical testing laboratory, which specializes in performing these complex tests. We conduct complex and specialized testing, including molecular diagnostics, in our world renowned Quest Diagnostics Nichols Institute laboratory facilities, and in a number of other locations, including Focus Diagnostics." }, { "bbox": [ 0.10217192793762309, 0.8881749412565852, 0.8793710484038143, 0.9317459359784084 ], "data": [], "index_in_doc": 93, "label": "text", "text": "Our esoteric laboratories provide reference testing services to physicians, large academic medical centers, hospitals and other commercial laboratories. Our esoteric testing laboratories perform hundreds of complex tests that are not routinely performed by our regional laboratories, including but not limited to the following fields:" }, { "bbox": [ 0.4942688696815402, 0.9495886246058828, 0.5040103033012023, 0.959552555400902 ], "data": [], "index_in_doc": 94, "label": "page_footer", "text": "4" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 6 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-7
/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trimmed-541453a0/hub/datasets--chicham--test_wds_trimmed/snapshots/1616e635480673f10910f640f0ba27d202407bab/document-0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff.tar.gz
- · endocrinology and metabolism (the study of glands, their hormone secretions and their effects on body growth and metabolism); - · genetics (the study of chromosomes, genes and their protein products and effects); - · hematology (the study of blood and bone marrow cells) and coagulation (the process of blood clotting); - · immunogenetics and human leukocyte antigens (solid organ and bone marrow transplantation; eligibility for vaccines; selection of pharmacotherapeutic agents and immunotherapy); - · immunology (the study of the immune system, including antibodies, cytokines, immune system cells and their effect, receptor systems and autoimmune diseases); - · microbiology and infectious diseases (the study of microscopic forms of life, including parasites, bacteria, viruses, fungi and other infectious agents); - · oncology (the study of abnormal cell growth, including benign tumors and cancer); - · serology (a science dealing with body fluids and their analysis, including antibodies, proteins and other characteristics); and - · toxicology (the study of chemicals and drugs and their adverse effects on the body). We also offer gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. We believe that offering a full range of gene-based and other esoteric tests strengthens our market offering and market position and enhances our reputation as the nation's leading test provider. Scientific Innovation. We are a leading innovator in the clinical testing industry, with capabilities ranging from early discovery to validation of clinical tests. We develop tests at our laboratories, such as Quest Diagnostics Nichols Institute; we also develop innovative techniques in anatomic pathology. We collaborate with leading academic centers and maintain relationships with advisors and consultants that are leaders in key fields, such as cardiology, oncology and infectious disease. In connection with our research and development efforts, our medical and scientific experts publish in peer-reviewed journals research that demonstrates the clinical value and importance of diagnostic testing. In 2010, they published more than 30 articles that provided fundamental insights into the biology of diseases or introduced novel diagnostic testing approaches benefitting patients. They also help to shape the latest thinking as the authors of textbooks, or chapters therein, used by academic institutions to train healthcare providers. We successfully transfer technical innovations to the market through our relationships with technology developers, including the academic community and pharmaceutical and biotechnology firms, our inhouse expertise and our collaborations with emerging medical technology companies that develop and commercialize novel diagnostics, pharmaceutical and device technologies. We search for new opportunities and continue to build a robust pipeline of new tests in predisposition, screening, diagnosis, prognosis and treatment choice, which assists physicians in early detection of diseases and may reduce healthcare costs. Through our strengths in assay development and the commercialization of test services, we believe that we are the partner of choice for developers of new technologies and tests to introduce their products to the marketplace. We focus our resources on key disease states and technologies that help doctors care for their patients through better predisposition, screening, monitoring, diagnosis, prognosis and treatment choices. We also look for tests that are less invasive than currently available options, to increase the choices that physicians and patients have for the collection of diagnostic samples. With these priorities in mind, we recently introduced a number of new or enhanced tests, including those discussed below. · Cancer. - - In 2010, we introduced our Lung Cancer Mutation assays, designed to aid treatment selection for lung cancer patients. These assays detect mutations in the EFGR, ALK and KRAS genes. These assays, together with our numerous other tests for lung cancer mutations, are designed to provide the most comprehensive lung cancer test offerings available from a commercial laboratory. - - We enhanced our Colorectal Cancer Mutation assay offering, which helps identify genetic mutations in the KRAS, PIK3CA, NRAS and BRAF genes that inhibit anti-epidermal growth factor receptor therapy response in metastatic colorectal cancer patients. - - We introduced our ColoVantage TM test, a blood test designed to aid in the detection of colorectal cancer, based on DNA methylation of the Septin 9 gene. We were the first commercial laboratory in the U.S. to offer a laboratory developed test based on the Septin 9 biomarker. - - After closely collaborating with Vermillion, Inc. on the commericialization of its FDA-cleared OVA1 TM ovarian cancer test, we launched the test in the first quarter of 2010. This multi-analyte test, which uses a proprietary algorithm, provides a new option for helping physicians assess if a woman's ovarian mass 5
[ { "bbox": [ 0.13735195178890702, 0.04548896409542624, 0.14329976703397077, 0.05008219089240102 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.1527336715268061, 0.0428169805884818, 0.8653502709434597, 0.05425549893239144 ], "ocr": false, "ocr_confidence": 1, "text": "endocrinology and metabolism (the study of glands, their hormone secretions and their effects on body" }, { "bbox": [ 0.15278324361266585, 0.05802175002993295, 0.322408495850824, 0.06946026837384259 ], "ocr": false, "ocr_confidence": 1, "text": "growth and metabolism);" }, { "bbox": [ 0.13735195178890702, 0.08118385129809227, 0.14329976703397077, 0.08577707809506704 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15278324361266585, 0.07851186779114783, 0.7220343594527363, 0.08995038613505747 ], "ocr": false, "ocr_confidence": 1, "text": "genetics (the study of chromosomes, genes and their protein products and effects);" }, { "bbox": [ 0.13735195178890702, 0.10167396905930715, 0.14329976703397077, 0.10626719585628193 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15246932502607405, 0.09900198555236271, 0.8717011662067268, 0.11044050389627234 ], "ocr": false, "ocr_confidence": 1, "text": "hematology (the study of blood and bone marrow cells) and coagulation (the process of blood clotting);" }, { "bbox": [ 0.13735195178890702, 0.12216408682052203, 0.14329976703397077, 0.12675731361749681 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15258498057401793, 0.11949210331357758, 0.8718660522258499, 0.13093062165748723 ], "ocr": false, "ocr_confidence": 1, "text": "immunogenetics and human leukocyte antigens (solid organ and bone marrow transplantation; eligibility" }, { "bbox": [ 0.15265106403610204, 0.13476936661877395, 0.6707377014666253, 0.14620788496268358 ], "ocr": false, "ocr_confidence": 1, "text": "for vaccines; selection of pharmacotherapeutic agents and immunotherapy);" }, { "bbox": [ 0.13735195178890702, 0.15793146788693327, 0.14329976703397077, 0.16252469468390804 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15258498057401793, 0.15525948437998882, 0.8778190549530991, 0.16669800272389848 ], "ocr": false, "ocr_confidence": 1, "text": "immunology (the study of the immune system, including antibodies, cytokines, immune system cells and" }, { "bbox": [ 0.15253542114055374, 0.17046425382143998, 0.5402226740645729, 0.1819027721653496 ], "ocr": false, "ocr_confidence": 1, "text": "their effect, receptor systems and autoimmune diseases);" }, { "bbox": [ 0.13735195178890702, 0.1936263550895993, 0.14329976703397077, 0.19821958188657407 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15258498057401793, 0.19095437158265485, 0.884392936035966, 0.20239288992656448 ], "ocr": false, "ocr_confidence": 1, "text": "microbiology and infectious diseases (the study of microscopic forms of life, including parasites, bacteria," }, { "bbox": [ 0.1526345526598777, 0.2062316348878512, 0.44516983158750517, 0.21767015323176087 ], "ocr": false, "ocr_confidence": 1, "text": "viruses, fungi and other infectious agents);" }, { "bbox": [ 0.13735195178890702, 0.22939373615601052, 0.14329976703397077, 0.23398696295298532 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15279976764128575, 0.2267217526490661, 0.7277574428476109, 0.23816027099297574 ], "ocr": false, "ocr_confidence": 1, "text": "oncology (the study of abnormal cell growth, including benign tumors and cancer);" }, { "bbox": [ 0.13735195178890702, 0.24988385391722542, 0.14329976703397077, 0.25447708071420017 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15316324566134173, 0.24721187041028098, 0.8682133562331571, 0.2586503887541906 ], "ocr": false, "ocr_confidence": 1, "text": "serology (a science dealing with body fluids and their analysis, including antibodies, proteins and other" }, { "bbox": [ 0.1527336715268061, 0.26248913371547733, 0.2876765059792185, 0.27340600804198595 ], "ocr": false, "ocr_confidence": 1, "text": "characteristics); and" }, { "bbox": [ 0.13735195178890702, 0.28557874111989145, 0.14329976703397077, 0.2901719679168662 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15253542114055374, 0.282906757612947, 0.736707291990568, 0.29434527595685667 ], "ocr": false, "ocr_confidence": 1, "text": "toxicology (the study of chemicals and drugs and their adverse effects on the body)." }, { "bbox": [ 0.13660847172017518, 0.3033968753741619, 0.8671229221729893, 0.3148353937180715 ], "ocr": false, "ocr_confidence": 1, "text": "We also offer gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. We" }, { "bbox": [ 0.10357493310425411, 0.31867413867935823, 0.8478273103881634, 0.33011265702326786 ], "ocr": false, "ocr_confidence": 1, "text": "believe that offering a full range of gene-based and other esoteric tests strengthens our market offering and" }, { "bbox": [ 0.10378971384532416, 0.3339514019845546, 0.6660504443926202, 0.3453899203284642 ], "ocr": false, "ocr_confidence": 1, "text": "market position and enhances our reputation as the nation’s leading test provider." }, { "bbox": [ 0.13680673475882307, 0.3544415197457695, 0.8675709181954809, 0.3658800380896791 ], "ocr": false, "ocr_confidence": 1, "text": "Scientific Innovation. We are a leading innovator in the clinical testing industry, with capabilities ranging" }, { "bbox": [ 0.10385746109742627, 0.36971878305096584, 0.8157304602475902, 0.38115730139487547 ], "ocr": false, "ocr_confidence": 1, "text": "from early discovery to validation of clinical tests. We develop tests at our laboratories, such as Quest" }, { "bbox": [ 0.10379137130914438, 0.3849960463561622, 0.885324658446051, 0.3964345647000718 ], "ocr": false, "ocr_confidence": 1, "text": "Diagnostics Nichols Institute; we also develop innovative techniques in anatomic pathology. We collaborate with" }, { "bbox": [ 0.10384093706880636, 0.4002007768224178, 0.8773430212220149, 0.4116392951663274 ], "ocr": false, "ocr_confidence": 1, "text": "leading academic centers and maintain relationships with advisors and consultants that are leaders in key fields," }, { "bbox": [ 0.10436963007027039, 0.41547804012761413, 0.8940779905809494, 0.42691655847152377 ], "ocr": false, "ocr_confidence": 1, "text": "such as cardiology, oncology and infectious disease. In connection with our research and development efforts, our" }, { "bbox": [ 0.10379137130914438, 0.4307553034328105, 0.8852486428534412, 0.4421938217767201 ], "ocr": false, "ocr_confidence": 1, "text": "medical and scientific experts publish in peer-reviewed journals research that demonstrates the clinical value and" }, { "bbox": [ 0.10379137130914438, 0.44603256673800684, 0.8934171306553171, 0.45747108508191653 ], "ocr": false, "ocr_confidence": 1, "text": "importance of diagnostic testing. In 2010, they published more than 30 articles that provided fundamental insights" }, { "bbox": [ 0.10379137130914438, 0.46130983004320325, 0.8894502503757256, 0.4727483483871129 ], "ocr": false, "ocr_confidence": 1, "text": "into the biology of diseases or introduced novel diagnostic testing approaches benefitting patients. They also help" }, { "bbox": [ 0.10374180554948241, 0.47658705437320403, 0.8910212730293843, 0.48802557271711366 ], "ocr": false, "ocr_confidence": 1, "text": "to shape the latest thinking as the authors of textbooks, or chapters therein, used by academic institutions to train" }, { "bbox": [ 0.1036757220873983, 0.4918643176784004, 0.8805284895509432, 0.5033028360223101 ], "ocr": false, "ocr_confidence": 1, "text": "healthcare providers. We successfully transfer technical innovations to the market through our relationships with" }, { "bbox": [ 0.10374180554948241, 0.5071415420084012, 0.8744007825456053, 0.5185800603523109 ], "ocr": false, "ocr_confidence": 1, "text": "technology developers, including the academic community and pharmaceutical and biotechnology firms, our in\u0002" }, { "bbox": [ 0.1036757220873983, 0.5223462724746568, 0.8094686378491657, 0.5337847908185664 ], "ocr": false, "ocr_confidence": 1, "text": "house expertise and our collaborations with emerging medical technology companies that develop and" }, { "bbox": [ 0.10394006858813032, 0.5376235357798531, 0.8741528968115153, 0.5490620541237627 ], "ocr": false, "ocr_confidence": 1, "text": "commercialize novel diagnostics, pharmaceutical and device technologies. We search for new opportunities and" }, { "bbox": [ 0.10394006858813032, 0.5529007601098539, 0.8727814783504353, 0.5643392784537635 ], "ocr": false, "ocr_confidence": 1, "text": "continue to build a robust pipeline of new tests in predisposition, screening, diagnosis, prognosis and treatment" }, { "bbox": [ 0.10394006858813032, 0.5681780234150503, 0.8560963088204809, 0.5796165417589599 ], "ocr": false, "ocr_confidence": 1, "text": "choice, which assists physicians in early detection of diseases and may reduce healthcare costs. Through our" }, { "bbox": [ 0.10436963007027039, 0.5834552477450511, 0.8827522745970667, 0.5948937660889607 ], "ocr": false, "ocr_confidence": 1, "text": "strengths in assay development and the commercialization of test services, we believe that we are the partner of" }, { "bbox": [ 0.10394006858813032, 0.5987325110502475, 0.7866405784391843, 0.6101710293941571 ], "ocr": false, "ocr_confidence": 1, "text": "choice for developers of new technologies and tests to introduce their products to the marketplace." }, { "bbox": [ 0.13661011653159982, 0.6192226288114623, 0.8461766788615516, 0.6306611471553719 ], "ocr": false, "ocr_confidence": 1, "text": "We focus our resources on key disease states and technologies that help doctors care for their patients" }, { "bbox": [ 0.10374180554948241, 0.6344998921166587, 0.8895311244882359, 0.6459384104605683 ], "ocr": false, "ocr_confidence": 1, "text": "through better predisposition, screening, monitoring, diagnosis, prognosis and treatment choices. We also look for" }, { "bbox": [ 0.10374180554948241, 0.6497046225829143, 0.8693994424038661, 0.6611431409268239 ], "ocr": false, "ocr_confidence": 1, "text": "tests that are less invasive than currently available options, to increase the choices that physicians and patients" }, { "bbox": [ 0.1036757220873983, 0.6649818469129151, 0.8831307330534826, 0.6764203652568247 ], "ocr": false, "ocr_confidence": 1, "text": "have for the collection of diagnostic samples. With these priorities in mind, we recently introduced a number of" }, { "bbox": [ 0.10379137130914438, 0.6802590907305136, 0.4902791644803327, 0.6916976285620211 ], "ocr": false, "ocr_confidence": 1, "text": "new or enhanced tests, including those discussed below." }, { "bbox": [ 0.13735359660033167, 0.7034211725110752, 0.1433014118453954, 0.70801439930805 ], "ocr": false, "ocr_confidence": 1, "text": "• " }, { "bbox": [ 0.15278368644651094, 0.7008476208605224, 0.2022332085503472, 0.7096014692713322 ], "ocr": false, "ocr_confidence": 1, "text": "Cancer." }, { "bbox": [ 0.15371716753958073, 0.7212486802998783, 0.8774460623315713, 0.7326872181313857 ], "ocr": false, "ocr_confidence": 1, "text": "- In 2010, we introduced our Lung Cancer Mutation assays, designed to aid treatment selection for lung" }, { "bbox": [ 0.1672120987874754, 0.7365259241174769, 0.8506940395677861, 0.7479644619489842 ], "ocr": false, "ocr_confidence": 1, "text": "cancer patients. These assays detect mutations in the EFGR, ALK and KRAS genes. These assays," }, { "bbox": [ 0.16701384840122305, 0.7518031874226732, 0.8544199170164801, 0.7632417252541807 ], "ocr": false, "ocr_confidence": 1, "text": "together with our numerous other tests for lung cancer mutations, are designed to provide the most" }, { "bbox": [ 0.1672120987874754, 0.7670079178889287, 0.729788506604348, 0.7784464557204362 ], "ocr": false, "ocr_confidence": 1, "text": "comprehensive lung cancer test offerings available from a commercial laboratory." }, { "bbox": [ 0.15371716753958073, 0.7874980551377414, 0.8812873296279021, 0.7989365929692489 ], "ocr": false, "ocr_confidence": 1, "text": "- We enhanced our Colorectal Cancer Mutation assay offering, which helps identify genetic mutations in" }, { "bbox": [ 0.16701384840122305, 0.8027753184429378, 0.8834105028244196, 0.8142138562744452 ], "ocr": false, "ocr_confidence": 1, "text": "the KRAS, PIK3CA, NRAS and BRAF genes that inhibit anti-epidermal growth factor receptor therapy" }, { "bbox": [ 0.16688166882465927, 0.8180525622605364, 0.500600634522699, 0.8294783746906929 ], "ocr": false, "ocr_confidence": 1, "text": "response in metastatic colorectal cancer patients." }, { "bbox": [ 0.15371716753958073, 0.8385426897655501, 0.3890592407429001, 0.8499812373408565 ], "ocr": false, "ocr_confidence": 1, "text": "- We introduced our ColoVantage" }, { "bbox": [ 0.3897084351598129, 0.8380071316033335, 0.4051454711711624, 0.8433975667941311 ], "ocr": false, "ocr_confidence": 1, "text": "TM " }, { "bbox": [ 0.41202574266525444, 0.8385448821203005, 0.8429156504262542, 0.8499834296956068 ], "ocr": false, "ocr_confidence": 1, "text": "test, a blood test designed to aid in the detection of colorectal" }, { "bbox": [ 0.1672134146366151, 0.8538221454254968, 0.8944697087479271, 0.8652606930008032 ], "ocr": false, "ocr_confidence": 1, "text": "cancer, based on DNA methylation of the Septin 9 gene. We were the first commercial laboratory in the" }, { "bbox": [ 0.1670316756265871, 0.8690993989868944, 0.6811844808347585, 0.8805379465622006 ], "ocr": false, "ocr_confidence": 1, "text": "U.S. to offer a laboratory developed test based on the Septin 9 biomarker." }, { "bbox": [ 0.15371849604111604, 0.8895170033967662, 0.8682399768734452, 0.9009555509720726 ], "ocr": false, "ocr_confidence": 1, "text": "- After closely collaborating with Vermillion, Inc. on the commericialization of its FDA-cleared OVA1" }, { "bbox": [ 0.8701406703461857, 0.8890524775284613, 0.8855777063575352, 0.8944429127192589 ], "ocr": false, "ocr_confidence": 1, "text": "TM" }, { "bbox": [ 0.1672789666980851, 0.9047950754372706, 0.8900941054817061, 0.9162336230125768 ], "ocr": false, "ocr_confidence": 1, "text": "ovarian cancer test, we launched the test in the first quarter of 2010. This multi-analyte test, which uses" }, { "bbox": [ 0.16741113362225332, 0.9200723387424669, 0.8865552810491811, 0.9315108765739742 ], "ocr": false, "ocr_confidence": 1, "text": "a proprietary algorithm, provides a new option for helping physicians assess if a woman’s ovarian mass" }, { "bbox": [ 0.4963900691043481, 0.9505632383461047, 0.5030978631419725, 0.9594697745214782 ], "ocr": false, "ocr_confidence": 1, "text": "5" } ]
[ { "bbox": [ 0.1354850528647453, 0.04218947993993455, 0.8660067784450145, 0.06946026837384259 ], "data": [], "index_in_doc": 95, "label": "text", "text": "- · endocrinology and metabolism (the study of glands, their hormone secretions and their effects on body growth and metabolism);" }, { "bbox": [ 0.13555281909544076, 0.07743950426045658, 0.7233068867900083, 0.09003348125199553 ], "data": [], "index_in_doc": 96, "label": "text", "text": "- · genetics (the study of chromosomes, genes and their protein products and effects);" }, { "bbox": [ 0.13560173325673067, 0.09847410550367178, 0.8725141585367434, 0.11105389552402618 ], "data": [], "index_in_doc": 97, "label": "text", "text": "- · hematology (the study of blood and bone marrow cells) and coagulation (the process of blood clotting);" }, { "bbox": [ 0.135896053282578, 0.11903515812080939, 0.8718660522258499, 0.14720876798471424 ], "data": [], "index_in_doc": 98, "label": "text", "text": "- · immunogenetics and human leukocyte antigens (solid organ and bone marrow transplantation; eligibility for vaccines; selection of pharmacotherapeutic agents and immunotherapy);" }, { "bbox": [ 0.13596996857752255, 0.1545859930006785, 0.8780872857392724, 0.18270511554118773 ], "data": [], "index_in_doc": 99, "label": "text", "text": "- · immunology (the study of the immune system, including antibodies, cytokines, immune system cells and their effect, receptor systems and autoimmune diseases);" }, { "bbox": [ 0.13562244522828565, 0.19034659238306195, 0.8851276859517516, 0.21798951598419541 ], "data": [], "index_in_doc": 100, "label": "text", "text": "- · microbiology and infectious diseases (the study of microscopic forms of life, including parasites, bacteria, viruses, fungi and other infectious agents);" }, { "bbox": [ 0.13594409442857328, 0.22623027543303, 0.7284442148793792, 0.2387972815892401 ], "data": [], "index_in_doc": 101, "label": "text", "text": "- · oncology (the study of abnormal cell growth, including benign tumors and cancer);" }, { "bbox": [ 0.13592839280566568, 0.24655911383500959, 0.8689205745361733, 0.27388353213801087 ], "data": [], "index_in_doc": 102, "label": "text", "text": "- · serology (a science dealing with body fluids and their analysis, including antibodies, proteins and other characteristics); and" }, { "bbox": [ 0.13572409457432888, 0.2823462943007663, 0.7379240981777312, 0.2950273418791906 ], "data": [], "index_in_doc": 103, "label": "text", "text": "- · toxicology (the study of chemicals and drugs and their adverse effects on the body)." }, { "bbox": [ 0.10206696366393941, 0.3025663139567369, 0.8677535175684079, 0.3463402135466555 ], "data": [], "index_in_doc": 104, "label": "text", "text": "We also offer gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. We believe that offering a full range of gene-based and other esoteric tests strengthens our market offering and market position and enhances our reputation as the nation's leading test provider." }, { "bbox": [ 0.10213127579064314, 0.35383826166886173, 0.8947023103881634, 0.6108996316999921 ], "data": [], "index_in_doc": 105, "label": "text", "text": "Scientific Innovation. We are a leading innovator in the clinical testing industry, with capabilities ranging from early discovery to validation of clinical tests. We develop tests at our laboratories, such as Quest Diagnostics Nichols Institute; we also develop innovative techniques in anatomic pathology. We collaborate with leading academic centers and maintain relationships with advisors and consultants that are leaders in key fields, such as cardiology, oncology and infectious disease. In connection with our research and development efforts, our medical and scientific experts publish in peer-reviewed journals research that demonstrates the clinical value and importance of diagnostic testing. In 2010, they published more than 30 articles that provided fundamental insights into the biology of diseases or introduced novel diagnostic testing approaches benefitting patients. They also help to shape the latest thinking as the authors of textbooks, or chapters therein, used by academic institutions to train healthcare providers. We successfully transfer technical innovations to the market through our relationships with technology developers, including the academic community and pharmaceutical and biotechnology firms, our inhouse expertise and our collaborations with emerging medical technology companies that develop and commercialize novel diagnostics, pharmaceutical and device technologies. We search for new opportunities and continue to build a robust pipeline of new tests in predisposition, screening, diagnosis, prognosis and treatment choice, which assists physicians in early detection of diseases and may reduce healthcare costs. Through our strengths in assay development and the commercialization of test services, we believe that we are the partner of choice for developers of new technologies and tests to introduce their products to the marketplace." }, { "bbox": [ 0.10202700107251826, 0.6185978174514088, 0.8908045627979893, 0.6919303884299169 ], "data": [], "index_in_doc": 106, "label": "text", "text": "We focus our resources on key disease states and technologies that help doctors care for their patients through better predisposition, screening, monitoring, diagnosis, prognosis and treatment choices. We also look for tests that are less invasive than currently available options, to increase the choices that physicians and patients have for the collection of diagnostic samples. With these priorities in mind, we recently introduced a number of new or enhanced tests, including those discussed below." }, { "bbox": [ 0.1356491038257605, 0.7005008000828145, 0.20342679759163168, 0.7129996775971823 ], "data": [], "index_in_doc": 107, "label": "section_header", "text": "· Cancer." }, { "bbox": [ 0.1516933156483209, 0.7206758423631067, 0.8783570348129146, 0.7785692080988585 ], "data": [], "index_in_doc": 108, "label": "text", "text": "- - In 2010, we introduced our Lung Cancer Mutation assays, designed to aid treatment selection for lung cancer patients. These assays detect mutations in the EFGR, ALK and KRAS genes. These assays, together with our numerous other tests for lung cancer mutations, are designed to provide the most comprehensive lung cancer test offerings available from a commercial laboratory." }, { "bbox": [ 0.15151885176574809, 0.7868786418422733, 0.8839485839033997, 0.8294783746906929 ], "data": [], "index_in_doc": 109, "label": "text", "text": "- - We enhanced our Colorectal Cancer Mutation assay offering, which helps identify genetic mutations in the KRAS, PIK3CA, NRAS and BRAF genes that inhibit anti-epidermal growth factor receptor therapy response in metastatic colorectal cancer patients." }, { "bbox": [ 0.15140968689673379, 0.8373561191680635, 0.8949945301163453, 0.8805379465622006 ], "data": [], "index_in_doc": 110, "label": "text", "text": "- - We introduced our ColoVantage TM test, a blood test designed to aid in the detection of colorectal cancer, based on DNA methylation of the Septin 9 gene. We were the first commercial laboratory in the U.S. to offer a laboratory developed test based on the Septin 9 biomarker." }, { "bbox": [ 0.15185096449717558, 0.8881592732279694, 0.8906275304791148, 0.9315688326897749 ], "data": [], "index_in_doc": 111, "label": "text", "text": "- - After closely collaborating with Vermillion, Inc. on the commericialization of its FDA-cleared OVA1 TM ovarian cancer test, we launched the test in the first quarter of 2010. This multi-analyte test, which uses a proprietary algorithm, provides a new option for helping physicians assess if a woman's ovarian mass" }, { "bbox": [ 0.4947335668661899, 0.9498938003871328, 0.5036245064553534, 0.9600254804238506 ], "data": [], "index_in_doc": 112, "label": "page_footer", "text": "5" } ]
{ "filename": "NYSE_DGX_2010.pdf", "page": 7 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-8
"/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trim(...TRUNCATED)
"is benign or malignant prior to a planned surgery. This information is expected to help physicians (...TRUNCATED)
[{"bbox":[0.16706417963081727,0.0428169805884818,0.8466470949290008,0.05425549893239144],"ocr":false(...TRUNCATED)
[{"bbox":[0.1654267065956027,0.042257140879430076,0.8623988213230721,0.08496577042424969],"data":[],(...TRUNCATED)
{ "filename": "NYSE_DGX_2010.pdf", "page": 8 }
0016b2921d51c75060b784992d10b71416d1849bf36f762a483c119a43ac44ff-9
"/tmp/hf-datasets-cache/medium/datasets/99894119707309-config-parquet-and-info-chicham-test_wds_trim(...TRUNCATED)
"information to other practitioners and secure, Web-based laboratory results to their patients' pers(...TRUNCATED)
[{"bbox":[0.1037898909788622,0.04288924060105364,0.8484533509211754,0.054327758944963285],"ocr":fals(...TRUNCATED)
[{"bbox":[0.10225569944871994,0.042337429782287675,0.8862275333942268,0.0855206992586606],"data":[],(...TRUNCATED)
{ "filename": "NYSE_DGX_2010.pdf", "page": 9 }

No dataset card yet

New: Create and edit this dataset card directly on the website!

Contribute a Dataset Card
Downloads last month
2
Add dataset card